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Abstract 
 
Bisphenol A (BPA) is widely used in plastic products. It is classified as an Endocrine 
Disrupting Chemical and has been associated to several endocrine-related disorders. 
The widespread exposure and the health effects are of concern. Epidemiological studies 
and in vivo and in vitro experiments correlate the BPA exposure to alterations of 
pancreatic islets, liver and adipose tissue functions. Given these data, its prevalence in 
the environment and the presence in serum from humans worldwide, BPA may play a 
role in the rapid increase of incidence of metabolic disorders. 
In this work we studied the effects of low doses of BPA on ex vivo primary murine 
pancreatic islets through a toxicogenomical approach. We found, through trascriptome 
analysis,that BPA is able to alter the expression of specific genes involved in 
mitochondrial functions, ROS detoxification and insulin exocytosis signal generation. 
Moreover, we demonstrated that BPA exposure impairs islets viability and promotes 
apoptosis in dose-dependent manner. Finally, we assessed that this apoptosis triggering 
is due to a BPA-dependent increase of ROS that activate the NFkB pathway. Taken 
together, our results suggest that exposure to low doses of BPA interferes with 
mitochondrial functions, which, in turn, leads to intracellular ROS increase, NFkB 
pathway activation and, finally, to apoptosis. Therefore, this work confirms the 
detrimental effects of BPA on pancreatic islet functions, shedding a new light on its 
mechanism of action. 
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1 Introduction 
1.1 Endocrine Disrupting Chemicals 
Recently, it is emerging the idea that micro-traces of some environmental pollutants 
could modify organism responses, increase susceptibility to certain diseases, and have 
chronic effects visible only in long run. This has opened a new field in environmental 
toxicology with the identification of new class of compounds: Endocrine Disrupting 
Chemicals (EDCs). The US Environmental Protection Agency (EPA) defines the 
EDCs as “Exogenous agent that interferes with the production, release, transport, 
metabolism, binding action, or elimination of natural hormones in the body responsible 
for the maintenance of homeostasis and the regulation of developmental processes”. 
This group of molecules is highly heterogeneous and includes both synthetic and 
natural compounds, e.g. dioxin and dioxin-like compounds, polychlorinated biphenyls 
(PCBs) and Polybrominated biphenyls (PBBs) used in chemical and electronic 
industries, dichlorodiphenyltrichloroethane (DDT), chlorpyrifos and other pesticides, 
fungicides and weed killers, plasticizer and plastic constituent such as Bisphenol A 
(BPA) and phthalates, pharmaceuticals such as Diethylstilbestrol (DES), Plant Growth 
Regulators (PGRs) and phytoestrogens ( e.g. genistein, daidzein, coumestrol, 
resveratrol), heavy metals and metalloids. The sources of exposure to EDCs are diverse 
and vary widely around , the most part come from industrial and metropolitan pollution 
but they may be also found in many everyday products– including plastic bottles, metal 
food cans, detergents, flame-retardants, food, toys, cosmetics (Fig. 1)[1], [2], [3]. 
Exposure occurs through drinking contaminated water, breathing contaminated air, 
ingesting food, or through transdermal absorption. Furthermore, in utero and neonatal 
exposure and transgenerational effects, through the germline cells, are gaining more 
and more interest. 
 
6 
 
Industrialized areas are typically characterized by contamination from a wide range of 
industrial chemicals that may leach into soil and groundwater and contaminate air. 
These complex mixtures enter the food chain and, owing to bioaccumulation and 
biomagnification, accumulate in animals higher up the food chain such as humans. 
Furthermore, several EDCs were designed to have long half-lives and, although this 
was beneficial for their industrial use, it has turned out to be quite detrimental to 
wildlife and humans. Because these substances do not decay easily, even substances 
that were banned decades ago remain in high levels in the environment. Some 
endocrine disruptors are detectable in so-called “pristine” environments at remote 
distances from the site they were produced, used, or released due to water and air 
currents, to become incorporated into the food chain in an otherwise uncontaminated 
region. Others, such as BPA, may not be as persistent, although recent evidence 
suggests longer half-lives  but are so widespread in their use that there is a prevalent 
human exposure. In the human body, due to their lipophilicity, they accumulate in 
adipose tissue, where thay can be retrieved unmetabolized or metabolized into more 
toxic compounds than the parent molecules. From this tisuue they are slowly released 
 
Fig.1 Sources of EDCs 
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and can be detected as part of the body burden of virtually every tested individual 
animal or human [4], [5].  
1.1.1 Low Dose  
One of the main feature of EDCs is their ability to exert their effects at very low 
concentrations. Indeed, the term “low dose” has become common to indicate the 
physiologically and pathologically relevant dose of an EDC [6].It is well established 
in the endocrine literature that natural hormones act at extremely low serum 
concentrations, typically in the picomolar to nanomolar range. Many studies published 
in the peer-reviewed literature document that EDCs can act in the nanomolar to 
micromolar range, and some show activity at picomolar levels. The Low Dose is 
considerably lower than the doses usually used in standard toxicological tests and than 
of the previously set LOAEL and NOAEL. The Low Dose is also frequently 
comparable to environmental concentration and to concentration measured in human 
fluids of EDCs [7].  
1.1.2 Non monotonic dose response curve 
Another EDC distinctive feature is the non-monotonic dose response curve. 
Classically, it was assumed that curves describing dose and response are monotonic, 
i.e. dose escalation leads to a greater effect and the slope never reverses from positive 
to negative or vice versa. For EDCs non-monotonic curves, including “U-shaped” or 
“inverted-U-shaped” dose response relationships, have been described [8]. The reasons 
why dose responses to toxicants may be non-monotonic can be manifold: the activation 
of metabolizing enzymes or conjugation substrates may result in a U-shaped dose 
response for some endpoints, with effects at low and at high levels of exposure, and 
diminished or nonexistent effects at intermediate levels, due to metabolic clearance. 
Furthermore, adaptive responses through complex cell signaling pathways and 
feedback mechanisms could cause non-monotonic effects that are inconsistent with the 
traditionally expected dose-response curves based on extrapolation of high dose data 
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predicting a decreasing effect for lower doses. Finally, the EDCs could have multiple 
targets with different affinity either in an organism or in an organ or even in single 
cells. Therefore, when in low concentration, they may be able to bind only some 
targets, while at higher concentrations can bind other targets producing changes in the 
effects and causing non-monotonic dose-response curve.  
1.1.3 EDCs - Mechanisms of Action 
Our understanding of the mechanisms by which EDCs exert their effect has grown. 
They were originally thought to exert actions primarily through nuclear hormone 
receptors, including estrogen receptors (ERs), androgen receptors (ARs), progesterone 
receptors, thyroid receptors (TRs), and retinoid receptors, among others. Today, basic 
scientific research shows that the mechanisms are much broader than originally 
recognized. Thus, endocrine disruptors act via nuclear receptors, non-nuclear steroid 
hormone receptors (e.g., membrane ERs), non-steroid receptors (e.g., neurotransmitter 
receptors), orphan receptors [e.g., aryl hydrocarbon receptor (AhR)], enzymatic 
pathways involved in steroid biosynthesis and/or metabolism, and numerous other 
mechanisms that converge upon endocrine system [9]. Binding these targets the EDCs 
can exert their effects in various ways such as having agonist or antagonist actions, 
competing for transport molecules, modifying natural hormones homeostasis 
(production and elimination), modifying hormone receptors expression, altering gene 
expression, disrupting epigenetic cells programming, disturbing intracellular 
transduction pathways [9].  
  
9 
 
A number of issues have proven to be key concepts to a full understanding of 
mechanisms of action and consequences of exposure to EDCs: 
 Latency from exposure 
 Age at exposure 
 Transgenerational, epigenetic effects 
 Cocktail effects 
 Nontraditional dose-response dynamics 
1.1.3.1 Age of exposure and critical windows 
Exposures to EDCs have different effects depending on the life stage of the exposed, 
fetus, infant or adult. Effects resulting from adult exposure are generally reversible and 
are termed “activational”. Effects resulting from exposure during organ development 
(beginning during prenatal development and continuing in postnatal life through 
puberty) may result in persistent alterations of the affected systems, even in the absence 
of subsequent exposure; these effects are termed “organizational” [10]. Some 
organizational effects are measurable immediately upon exposure and persist 
throughout the life [11]. Other organizational effects are undetectable at the time of 
exposure, but they become apparent in subsequent adulthood [10], [12] . Windows of 
vulnerability, also known as critical periods, during which the developing system is 
most sensitive to exposure, are common features of organizational effects [13]. 
Exposures occurring outside the critical periods will not elicit organizational effects. 
There is evidence that organizational effects of estrogenic endocrine disruptors such as 
BPA are mediated by epigenetic alterations in DNA [14]. Organizational and 
activational effects on the same tissue often differ qualitatively as well as in duration 
and in the dose required to elicit effects.  
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1.1.3.2 Transgenerational and epigenetic effects 
EDCs may affect not only the exposed individual but also subsequent generations. 
Recent evidence suggests that the mechanism of transmission may involve in some 
cases the germline and may be non-genomic. That is, transmitted effects may not be 
due to mutation of the DNA sequence, but rather due to modifications of epigenetic 
state of the cells. Generally, an epigenetic effect is defined as heritable changes in gene 
expression or cellular phenotype without any alterations in the DNA sequence, and its 
mechanisms include DNA methylation, histone modifications and expression of non-
coding RNAs (including microRNAs) [15]. Recent investigations have examined the 
relationships between exposure to environmental chemical xenobiotics and epigenetic 
effect induction and have reported that several toxicants have a potential role in 
modifying epigenetic marks [16]. In addition to epigenetic mechanism, reports shows 
that estrogens and xenoestrogens have the ability to cause genomic instability [17], 
[18], with improper chromosome segregation that can lead to chromosomic aberrations 
or aneuploidy in the progeny.  
1.1.3.3 Cocktail effects 
The large number of EDCs present in the environment raises questions about the effects 
of simultaneous exposure to multiple compounds. However, relatively few studies 
have discussed combination effects. For some authors effects of combined exposure to 
several (xeno)estrogens at equipotent concentrations were in high agreement with the 
predictions made with the model of concentration addition (based on the assumption 
that chemicals act via a similar mechanism) [19], [20]. Other endpoints, however, show 
far more complex outcomes after combined exposure. 
1.1.3.4 EDCs – cell targets  
Although EDCs can act through several mechanisms, most information is available 
about interference of EDCs with sex hormones, especially xenoestrogens.  
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1.1.3.4.1 Activation of the classical nuclear receptors.  
EDCs can bind nuclear receptors (NR) and act as agonist or antagonist. They can 
control gene networks and modulate target cell activities through the activation of NRs, 
which bind responsive elements in the promoters of target genes and regulate target 
gene expression [19]. After activation by binding to a ligand resulting in a 
conformation change, receptors can act as transcription factors, interacting with 
coactivators and corepressors and with DNA sequences [21], [22]. However, the 
change in conformation differs in function of the ligand [23]–[27]. That is what has 
been observed: receptors bound to xenobiotic ligands do not have exactly the same 
influence on gene expression as receptors bound by endogenous ligands [28], [29]. 
This has been studied for several EDCs, such as octylphenol, nonylphenol, endosulfan, 
kepone [30] and BPA and for the phytoestrogen coumestrol which has opposite effects 
on the regulation of estrogen receptors compared to 17-estradiol (E2) [31]. 
1.1.3.4.2 Activation of membrane-bound receptors 
Hormones can also induce non-genomic responses based on plasma membrane 
receptors (e.g. mERs, GPR30) and acting through second messenger-triggered signal 
cascades [32]. The rapid non-genomic mechanisms have been shown to interact with 
cytoplasm signal transduction molecules such as cAMP and adenylate cyclase, 
calcium, PI3K, PKB, and G-proteins or directly with secondary transcription factors 
such as AP-1, STATs, NFκB, and Sp1 [33][34]. These actions can result in several 
different effects, e.g. change in ions concentrations (Ca2+, K+) that can lead to cell 
motility or hormone exocytosis such as prolactin or insulin [35]. EDCs, such as 
dieldrin, endosulfan, nonylphenol, BPA, coumestrol, and DES are known to affect Ca2+ 
influx and PRL or insulin release. 
1.1.3.4.3 Cytoplasmic interactions 
Besides with nuclear-and plasma membrane-associated receptors, EDCs can also 
interact with targets within the cytosol. One of the best-studied examples is the 
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activation of Src/Ras/ERK (MAPK) pathway, in a mechanism linked to the 
proliferative effects of estrogens[36]. Another example is the modulation of nitric 
oxide (NO), with activation of endothelial NO synthase (eNOS, the enzyme 
responsible for NO production) [36].  
1.1.3.4.4 Activation of Estrogen-Related Receptors. 
A particular case is the bind of xenoestrogens to the Estrogen Related Receptors 
(ERRs). ERRs are a subfamily of orphan nuclear receptors closely related to ERα and 
ERβ. Three of these ERR are known: ERRα, ERRβ, and ERRγ. ER and ERR show a 
considerable amount of similarity in aminoacid sequence, but E2 does not bind ERRs. 
However, ERR can bind to estrogen response elements which suggests a possible 
overlap between ER and ERR action [35]. ERRs show spontaneous transcriptional 
activity, which is repressed by a few chemicals. For example, DES represses the 
molecular activities of ERRs. Another inverse agonist of ERRγ is 4-hydroxytamoxifen 
(4- OHT). On the other hand, bisphenol-A has been observed to have a distinct 
antagonist action to the inverse agonist activity of 4-OHT, thus preserving ERR-
activity in the presence of 4-OHT [37].  
1.1.3.4.5 Interference with hormones metabolism and hormonal feedback regulation. 
Along with the direct influence of EDCs on endocrine targets, they can affect 
endogenous hormones production through negative and positive feedback [4] or 
influencing enzymes involved in the process of hormones synthesis. They can also 
compete with endogenous hormones for transport molecules. 
For example, some EDCs, amongst others PCBs and BPA, can disrupt the link between 
neuroendocrine systems and peripheral endocrine systems for the control of 
homeostatic processes including reproduction, growth, metabolism, energy balance, 
and stress response. PCBs reduce the thyroxin and TSH (thyroid stimulating hormone) 
response to TRH (thyrotropin-releasing hormone), which result in metabolism and 
energy balance deregulation. Thyroid disruption also has consequences for neural 
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development [38]. Furthermore, the obesogenicity of DES has been supposed to 
involve action on the developing hypothalamic circuits, which are important for the 
energy balance [38]. 
An esplicative example of how EDCs influence the hormone synthesis is he case of 
xenoestrogen. Xenoestrogens have been shown to affect steroidogenic enzymes, 
including hydroxysteroid dehydrogenases, aromatase, sulphatases, and 
sulphotransferases. Mostly, steroidogenesis is inhibited by xenoestrogens [39]. 
Atrazine was observed to stimulate aromatase activity in some cell types, which leads 
to a higher synthesis of estradiol [40]. On the other hand, DDT and several metabolites 
were reported to inhibit aromatase activity in some cell types [39]. 
1.1.3.4.6 Cross-talk with other pathways after binding other receptors.  
The expression of many genes involved in xenobiotic/drug metabolism and transport 
is regulated by at least three nuclear receptors or xenosensors: aryl hydrocarbon 
receptor (AhR), constitutive androstane receptor (CAR), and pregnane X receptor 
(PXR). These receptors establish crosstalk with other nuclear receptors or transcription 
factors controlling signalling pathways that are important to the homeostasis [41]. For 
example, many drugs and environmental pollutants activate PXR. A significant 
proportion (54%) of compounds with estrogenic activity or those able to bind ER were 
found to be PXR activators (estradiol, ethynylestradiol, BPA, tamoxifen, phthalates, 
alkylphenols) [42]. The PXR, which regulates several cytochrome P450 enzymes 
crucial in the oxidative metabolism of a wide range of chemicals can, thus, play a role 
in the inactivation of toxic or carcinogenic chemicals, in the activation of pro-
carcinogens and could also act as a protector of the endocrine system from chemical 
perturbation [42]. The AhR is a ligand activated transcription factor and a key regulator 
of the cellular response to xenobiotic exposure. It belongs to the family of the bHLH-
PAS proteins, and is ubiquitously expressed and well conserved throughout evolution. 
It is strongly activated by organic compounds such as dioxins, PCDF, PCB and BPA 
[43] showed that the agonist-activated AhR/Arnt heterodimer directly associates with 
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estrogen receptors ER and ER. This association resulted in the recruitment of 
unliganded ER and the coactivator p300 to estrogen responsive gene promoters, 
leading to activation of transcription and estrogenic effects. 
1.1.4 Epidemiology of EDCs 
The endocrine related diseases and disorders are strongly increasing in the last 50 years. 
The speed with which the increases in disease incidence has occurred in recent decades 
rules out genetic factors as the sole plausible explanation. Environmental component 
and other non-genetic factors are supposed to play a role. Despite considerable public 
interest and research activity, the scope and magnitude of the impact of putative EDCs 
on human health are largely unknown. Exposures in some cases, have been unusually 
high, such as those from chemical spills or sewage out falls; therefore they are not 
typical of the ambient exposures normally encountered by wildlife or human 
populations. So one of the main challenges was, and still is, to demonstrate whether 
the low environmental concentrations of EDCs are detrimental for health or not. In 
wildlife, a number of adverse effects have been linked to specific EDCs. Effects linked 
to endocrine disruption have been largely noted in invertebrates, reptiles, fish, birds 
and mammals [44]. Over the last decade, scientific understanding of the relationship 
between exposure to endocrine disruptors and health has advanced rapidly. There is a 
growing concern that maternal, fetal and childhood exposure to EDCs could play a 
larger role in the causation of many endocrine diseases and disorders than previously 
believed. This is supported by studies of wildlife populations and of laboratory animals 
showing associations between exposure to EDCs and adverse health effects and by the 
fact that the increased incidence and prevalence of several endocrine disorders cannot 
be explained by genetic factors alone.  
There are several health problems worldwide with postulated association to the 
exposure to EDCs: decreased sperm counts/quality, increased incidence of 
hypospadias and cryptorchidism, altered birth sex ratios, miscarriage, increased 
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incidence of cancer, altered development, brain and behavior defects, impaired 
immune function, attention deficit hyperactivity disorder, hyper allergic diseases, 
asthma, obesity, heart disease and type two diabetes. Just some of the several 
recognized epidemiological associations between EDCs and pathologies and related 
published papers are listed in table 1. 
TABLE 1 Epidemiological associations between EDCs and disease 
DISORDER EPIDEMIOLOGICAL ASSOCIATED EDCs 
Abnormal sex ratio DES [45], PCBs [46], Dioxins [47] 
Negative pregnancy outcomes  Lead [48], BPA [43][47], Pesticides [50]–[52], Chlorpyrifos [53], DDT/DDE 
[54] 
PCOS BPA [55] 
Female sub-fecundity 
Lead [56], [57], Pesticides [58]–[62], DDT/DDE [63]–[65], PCBS [63], [66]–
[68] 
Female altered puberty beginning  DDT/DDE [69], [70], Dioxins [71], Lead [72], [73], PBBs [74], PCBs [72] 
Male urogenital malformations DES [75]–[77], DDT/DDE/DDE [78], PCBs [79], Phthalate [80] 
Poor sperm quality PCBs [81], [82], Dioxins [47], Phthalates [83], [84] 
Altered menstrual cycle  
Lead [48], Pesticides [85], DDT/DDE [86][69], PCBs [86], [87], Dioxins 
[88], Phytoestrogens [89] 
Breast cancer DES [90]–[92], Dioxins [93] 
Prostate cancer DES[90]–[92], Dioxins [93], Pesticides [94], [95], PCBs [96] 
Thyroid cancer Pesticides [97], [98], Dioxins [97], PCBs [98] 
Metabolic disorders  BPA Phthalates [101], DDT/DDE [102] 
 
However, whether or not endocrine disrupting compounds (EDCs) could be a 
contributing factor remains the subject of intense scrutiny and other determinants such 
as diet, stress, and body weight, likely, also play a role [4], [103]–[106]. 
The most commonly studied EDCs are DDT, PCBs, dioxins and BPA[104], [105] 
1.2 Bisphenol A 
BPA (2, 2-bis (4-hydroxyphenyl) propane) is a small (228 Da) molecule, composed by 
two phenolic functional groups [108]–[113]. It is prepared by the combination of two 
equivalents of phenol with one equivalent of acetone; it was first synthesized by A. P. 
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Dian in in 1891 and was later investigated in the 1930s during the search for synthetic 
estrogens [113].  
 
The BPA is used as monomer in polymerization reaction to produce polycarbonate 
plastics and epoxy resins and in the synthesis of polyesters, polysulfone, 
polyvinylchloride, and polyethylene terephthalate. Moreover, due to its ability to give 
plasticity and toughness, it is used as additive in production of nearly all plastics or 
plastic based materials. The BPA is among the highest-production-volume chemicals 
in the world, with an annual production of over 2 million tonnes [108], [113]. 
Therefore it is widely present in a multitude of everyday products, such as drinking 
water tanks and pipes, medical and dental devices (such as catheters and dental 
sealants), eyeglass lenses, CDs and DVDs, household electronics, paints, adhesives, 
food and beverage cans (as lining film), childhood products (such as toys and baby-
bottles), and in almost all plastic tools or products [113]–[116].  
The BPA is within these products as a polymer. In consequence of mechanical, 
chemical o physical stress (e.g. detergents, heat or aging), the BPA polymers break 
down, because of hydrolysis of ester bonds (Fig. 2), and the monomers can seep into 
water, foods and dust particles, contaminating the environment and providing ample 
 
Fig. 2 BPA polymers breakdown 
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entry ways for BPA into humans and animals. This process is commonly known as 
“leaching” [109], [111], [115], [116]. 
The primary source of exposure to BPA for most people is through the diet. While 
inhalation and transdermal absorption are other possible routes of exposure, BPA in 
food and beverages accounts for the majority of daily human exposure. 
Therefore, exposure to BPA is nearly ubiquitous. Measurements by American Centers 
for Disease Control (CDC) established that 92.6% of American citizens 6 years or older 
have detectable BPA levels in their urine  and its concentration in human serum ranges 
from 0.2 to 1.6 ng/ml (0.9-7 nM) [119]–[121]. 
A comprehensive, cross-sectional study of dust, indoor and outdoor air, and solid and 
liquid food in preschool-aged children suggests that dietary sources constitute 99% of 
BPA exposure [119]. For example, in a randomized control study, the researchers 
found that consumption of one serving of canned soup daily over 5 days was associated 
with a more than 1000% increase in urinary BPA [122]. Moreover, since BPA is a 
lipophilic compound it can also accumulate in fat, with detectable levels found in 50% 
of breast adipose tissue samples from women, suggesting that the compound 
accumulates in fat and other physiologic compartments [78]. 
Concerning the widespread exposure and the potential risk of this compound, in the 
1980s LOAEL for BPA was determined at 50mg/kg bw/day and the NOAEL at 5mg/ 
kg bw/day. These doses were established in a 2-year carcinogenesis study conducted 
in adult rodents exposed daily to high doses of BPA. Nevertheless, in 1988, the EPA 
calculated a ‘reference dose’’ or safe dose of 50 µg/kg bw/day in a series of studies in 
which the changes of body weight in animals fed diets containing BPA were analyzed 
[123]. This reference dose remains the current safety standard for BPA today despite 
new knowledge about BPA, including the numerous reports of non-monotonic dose 
response effects of BPA, and despite the numerous scientiﬁc evidence supports that 
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BPA can interfere with the endocrine signaling pathways at doses below the calculated 
safe dose [117], [123] 
1.2.1 BPA- Mechanisms of Action  
 
The BPA is basically known for being a xenoestrogen. Indeed, before its extensive use 
in chemical industry, it was originally investigated as synthetic estrogen but abandoned 
for pharmaceutical use because of the discovery in 1938 of DES with greater estrogenic 
effect [124]. The core structure of BPA resembles that of natural 17β-estradiol (E2) 
(Fig. 4) and fits in the ER binding pocket. This was confirmed by biochemical assays 
that examined the kinetics of BPA binding to ER and determined that BPA binds both 
ERα and ERβ [123][124].  
Therefore, the most literature converges on its effects on estrogens-responsive tissues 
or organs (specifically on reproductive system), mediated by classic nuclear ERs or 
novel transmembrane (GPR30) or membrane-bound ERs. 
Until recently, BPA was considered a weak environmental estrogen because of its 
affinity for the nuclear ERs is approximately 10000-fold weaker compared to estradiol 
[126]. However, recent studies confirmed that BPA is a SERM and can have agonist 
or antagonistic action on ERs. These actions, through a variety a pathways, can induce 
(or inhibit) cellular responses at very low concentrations, below the levels where BPA 
 
Fig. 3 Chemical Structure of BPA (A) and Estradiol (B). [316] 
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is expected to bind to the classical nuclear ERs (reviewed in [127]). Extensive 
biochemical studies of ERα have identified two distinct gene transactivating regions, 
termed AF1 (found in the amino terminus) and AF2 (located in the carboxyl terminus) 
[125].ER agonists are subdivided based on their ability to activate these regions. 
Binding of BPA to the ERs alters their ability to recruit co-activators and this may 
contribute to the complex tissue-specific responses to exposure, as well as to the dual 
action (agonistic and antagonistic) of the BPA [128]. For instance, BPA is able to alter 
the gene expression in cells containing ERβ where TIF2 is the main coactivator, but 
may be equally effective in cells expressing either ERα or ERβ if the steroid receptor 
coactivator-1a is present [129].  
Several membrane steroid receptors have been described, including a membrane-
bound form of ERs (mER) that is similar but not identical to the nuclear ERα 
[128][129] and a transmembrane ER called G protein-coupled receptor 30 (GPR30) 
[132]. BPA has been shown to bind to both mER and GPR30. Studies have determined 
that these membrane-bound receptors are capable of non-genomic steroid actions 
[130]–[133] (also reviewed in [128]). For example, GH3/B6 pituitary cells, which 
naturally express mER, respond to low-level BPA exposure by producing a calcium 
flux, which leads to prolactin release [131]. 
The antiandrogenic properties of BPA are still somewhat in dispute. There have been 
mixed results with mammalian cell reporter assays, i.e., some groups measured 
antiandrogenic activity of BPA with a half-maximal response at 2.14–3.2 μM 
[132][133], whereas others were unable to demonstrate any antagonist activity [136]. 
Additional studies indicate that BPA also binds to an orphan nuclear receptor called 
estrogen-related receptor-γ (ERR-γ) [137]. Although the endogenous ligand for ERR-
γ remains unknown, the human receptor behaves as a constitutive activator of 
transcription and may play a role in differentiation and maturation of the fetal brain 
[37]. 
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In addition to its estrogenic activity, there is some evidence that BPA binds to thyroid 
hormone receptor, acting as a thyroid hormone antagonist by preventing the binding of 
T3. The affinity of BPA for this receptor several-fold lower than its affinity for the 
ERs, nevertheless, at very low concentrations, it is able to inhibit the TR-induced gene 
expression recruiting the co-repressor N-COR [138]. Moreover, in a recent study we 
showed that very low concentration of BPA (10-9M or lower) is able to affect the 
pituitary-thyroid axis directly altering, in vivo and in vitro, the expression of genes 
involved in thyroid hormones synthesis (i.e. thyroblobulin, sodium iodide symporter) 
or their expression regulators (i.e PAX8 protein). This effect is not mediated neither by 
ERs nor by TRs, but mainly by retinoid acid receptors (RARs) and NF-kB [139]. 
BPA also binds the aryl hydrocarbon receptor (AhR) [135] but the effects remain 
unknown at this time. Because AhR can cross-talk with other receptors including ERs 
and the androgen receptor, endocrine-related endpoints may be affected by its 
activation (reviewed in [140]). It is also reported that BPA interacts with and activates 
human PXR (pregnane X receptor), a nuclear receptor that functions as a regulator of 
xenobiotics, acting as a potent agonist [141]. 
It has been reported that BPA can affect cell-signaling mechanisms by increasing 
intracellular calcium and phosphorylation of extracellular signal-regulated kinase 
(ERK) and c-Jun N-terminal kinase (JNK), and nuclear translocation of nuclear factor 
NF-kB [142]. 
Growing evidence suggests that BPA is associated with oxidative stress [141][142]. 
Indeed, it has been revealed that BPA can disturb oxidative homeostasis through direct 
or indirect pathways, including mitochondrial function [145], modulation of 
antioxidant enzymes and increase thiobarbituric acid-reactive substances in the brain, 
kidney and testis of mice exposed throughout embryonic/fetal route [146]. Oxidative 
stress has been implicated in aging and many pathological disorders, such as ischemic 
diseases, neurodegenerative diseases, diabetes, and cancer, although the underlying 
mechanisms are not always completely understood [147]. 
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Finally, BPA can alter cell function and response modifying epigenetic state of the 
cells. This is of particular concern when happen in germinal cells and in perinatal 
developmental tissue. In fact, epigenome alteration is probably the process that allow 
the BPA to change offspring phenotype, predisposing individuals to develop certain 
diseases in adulthood. Specifically it has been demonstrated that low dose of BPA 
(2x10-8 – 2x10-4 M) alters the gene expression of epigenetic regulatory factors such as 
DNA methyltransferases (DNMTs) and methyl-CpG binding protein 2 (MECP2) in a 
dose-dependent mechanism [148]. Moreover, BPA increases the expression of the 
histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) level [149], which is 
involved in maintaining the transcriptional repressive state of genes over successive 
cell generations [150]. In addition, BPA exposure has been shown to alter microRNA 
expression, in the fetal ewe ovary [151] and in human placental cell lines (miR-146a) 
 
Fig. 4 Cellular and molecular mechanisms of action of BPA in human disease 
induction. AR: androgen receptor, ER: estrogen receptor, ERK: extracellular signal-
regulated kinase, ERR-γ: estrogen-related receptor gamma, GPR 30: G protein-coupled 
receptor 30, GR: glucocorticoid receptor, JNK: c-Jun N-terminal kinase, NF-κb: nuclear 
factor-kappa B THR: thyroid hormone receptor. [9] 
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[152] suggesting a potential impact in reproductive system and developmental 
pathways.  
1.2.2 BPA - Health Issues 
Several publications associate low doses BPA exposure to endocrine-related disorders, 
anomalies and diseases. For example, since 2007, more than 50 epidemiology studies 
have examined various health outcomes in relation to BPA exposure and the number 
of experimental studies in vivo or in vitro is on the rise. The most of these studies use 
a dose or a concentration of BPA equal or below the EPA cut-off 1x10-7M or 
50ug/Kg/day. Nevertheless many studies examining doses at or below 1x10-9M report 
significant biological effects [153]–[166] challenging the hypothesis that BPA only has 
“weak” endocrine disrupting activity and suggesting that it may be reasonable shift 
down the reference safe dose set by EPA.  
In sum, the literature indicates there are reproducible effects of BPA exposures on a 
number of endpoints including reproductive system issue, hormonal related cancers, 
behaviors, liver function, thyroid hormone signaling and metabolic disorders.  
All experimental studies examined in the sections below, unless otherwise specified, 
use concentrations or doses equal to or lower than the EPA reference dose. 
 
1.2.2.1 Reproductive system  
Epidemiological studies indicate that BPA is related to decreased sperm quality (low 
concentration, count, vitality and motility) [167][168], male genital anomalies (shorter 
anogenital distance and cryptochidism) [169], [170], altered blood sex hormones levels 
(estrogens, androgens and gonadotropins) [169], [171]–[173][174], polycystic ovary 
syndrome [121], [175], [176] and endometrial disorders (e.g. endometriosis) [177], 
[178]. Investigations conducted in fertility centers have shown that high urinary level 
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of BPA are associated with poor ovarian response to hormone stimulation [179], 
[180]decreased probability of in vitro fertilization (55% lower for every doubling of 
BPA level) [181] and high probability of implantation failure [182]. Moreover, a study 
of Sugiura-Ogasawara et al. [49] demonstrated that women who experienced recurrent 
miscarriages had significantly higher total serum BPA than the healthy controls from 
the same town. Of the miscarriage patients who subsequently had successful 
pregnancies, there was a trend of less serum BPA. Probably, this increase in 
miscarriages is due to chromosomal anomalies (aberrations and aneuploidies), induced 
by BPA in oocytes [49], [183], [184].Several in vitro and in vivo studies confirm these 
negative outcomes in reproductive performances and in the disorders of the 
reproductive apparatus. Studies on cell lines or on ex vivo primary cells isolated from 
the reproductive tract identified several effects of BPA ranging from altered hormone 
secretion [185] to altered gene expression [186]–[188] and altered proliferation [157], 
[159], [189], [190]. Animal studies showed that BPA alters estrous cycles, number of 
oocytes, receptors expression and cell proliferation in multiple compartments of the 
uterus, testis weight at puberty and in adulthood and prostate size [113]. Furthermore, 
BPA was shown to induce hypermethylation of estrogen receptor promoter regions in 
rat testis, indicating in the epigenetic changes one of the possible mechanisms of BPA 
induced adverse effects on spermatogenesis and fertility [191]. 
  
1.2.2.2 Hormonal cancers 
The studies on effects of low doses of BPA on cancer induction are controversial, 
except for breast cancers. However, the idea that BPA can play a role in tumorigenesis 
and neoplastic progression of hormonal-dependent cancers is well accepted. Indeed, 
studies in rodents have shown that BPA induces mammary pre-neoplastic or neoplastic 
lesions [192]–[195]. Two studies in vivo and in vitro showed that low BPA doses can 
accelerate mammary tumorigenesis and metastasis in MMTV-erbB2 mice [196] and 
can induce a profile of tumor aggressiveness in high-risk cells from breast cancer 
24 
 
patients [197]. Another recent study revealed the presence of carcinomas in the 
mammary glands of rats exposed to low doses of BPA only during early development 
in the absence of any additional carcinogen treatment [198]. 
Furthermore, there is evidence from rodent models and human prostate cell lines that 
BPA can influence prostate carcinogenesis, modulating cancer cell proliferation and 
stimulate disease progression. The recent reports have provided evidence that early life 
exposure to BPA may increase susceptibility to hormonal carcinogenesis in the prostate 
gland, possibly by developmentally reprogramming carcinogenic risk [199]. Studies 
using a rat model showed that brief neonatal exposure to a low dose of BPA 
significantly increased the incidence and grade of prostatic intraepithelial neoplasia 
following adult estrogen exposure. This model of sensitivity to hormonal 
carcinogenesis is relevant to humans in that relative estradiol levels increase in the 
aging male and may contribute to prostate disease risk [200]. The above studies further 
identified alterations in DNA methylation patterns in multiple cell signaling genes in 
BPA-exposed prostates which suggest that environmentally relevant doses of BPA 
‘imprint’ the developing prostate through epigenetic alterations [199]. 
In vivo analyses of BPA impact on human prostate tumor growth and recurrence was 
performed utilizing a xenograft model [201]. Tumor size increased in response to BPA 
administration and mice in the BPA cohort demonstrated an earlier rise in PSA.  
Finally, Hiroi et al. have suggested the presence of associations between BPA exposure 
and complex endometrial hyperplasia and endometrial cancer [178]. 
 
1.2.2.3 Brain morphology, neuroendocrine signaling and behavior 
The most meaningful studies on the effects on brain development, neuroendocrine 
signaling, and behavior concern the in utero and perinatal exposure to BPA. The 
exposure of pups or of pregnant rats or mice to BPA results in an increased expression 
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of ERs [202] and ER- labeled neurons [203] in diverse brain areas and in a reduced 
number of dopamine containing neurons [204]. CD-1 mice developmental exposure to 
BPA result in a significant change in the locus coeruleus [205], [206] while maternal 
exposure disrupt normal neocortical development in fetuses by accelerating neuronal 
differentiation/migration [207]. Moreover, five studies have demonstrated low dose 
effects of adult BPA exposures on brain endpoints such as synapse formation and 
remodeling [208], [209]. Some of these effects were observed only in response to 
additional hormone treatments (e.g., BPA attenuates the effects of estrogens on synapse 
formation/ remodeling). Epidemiological studies examining neurobehavioral outcomes 
correlates pre-natal exposure to BPA exposure and neurobehavioral outcomes, such as 
aggressivity and hyperactivity [210] or anxious or depressed behavior with poor 
emotional control [211]. These observations are in agreement with results of behavioral 
tests conducted on laboratory rodents exposed to low doses of BPA such as anxious 
behavior , increase of aggressiveness, impaired learning, hyper-reactivity to painful or 
fear-provoking stimuli, altered adult play and other socio-sexual behaviors [212]–
[217].  
 
1.2.2.4 Liver function  
Studies in vitro and in vivo showed the effects of low doses of BPA (10-9M) are able 
to enhance the expression of liver enzymes and marker of oxidative stress and to alter 
the hepatic gene expression and potential markers of liver function [218]–[221]. 
Furthermore, three epidemiological studies correlate high level of urinary BPA with 
elevations in liver enzymes (e.g. alkaline phosphatase, lactate dehydrogenase and -
glutamyltransferase) [222]–[224]. 
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1.2.2.5 Thyroid function 
Various studies have investigated associations between BPA and thyroid dysfunction. 
This is of particular concern because thyroid hormones play an important role in 
controlling metabolism and brain development. In rats prenatal BPA exposure was 
associated with decreased TSH [225]and increased level of T3/T4 [226] in pups. 
Several cohorts studies suggest associations between elevated urinary BPA and low 
circulating TSH and or high T3/T4 [173], [227]; the altered levels of TSH was found 
also in newborn, which mothers were exposed to BPA [225]. Further, another 
epidemiological study found that individuals with increased thyroid function 
(hyperthyroid and sub-clinical hyperthyroid) has significantly higher BPA urinary 
levels than individuals with normal thyroid function (euthyroid), indicating higher 
BPA is associated with increased thyroid function [228]. All these studies are in 
agreement with our findings on enhanced expression of genes involved in thyroid 
hormones synthesis and in cell proliferation induced by low concentrations of BPA in 
vitro and in vivo [140]. 
 
1.2.2.6 Metabolism 
The endocrine system is involved in the control of metabolism, and important organs 
such as the pancreas and adipose tissue are endocrine organs. The thyroid gland is 
important in setting the basal metabolic rate, and the adrenal gland plays a role in 
glucose and lipid metabolism. Consequently, there is good reason to consider that 
endocrine disruption, and BPA, may be associated with disorders of metabolic 
function. 
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1.3 BPA and Metabolic Disorders  
The three main metabolic disorders are the metabolic syndrome, the obesity and the 
diabetes mellitus.  
The metabolic syndrome is a condition characterized by the presence of three out of 
five determinants: abdominal adiposity, hypertension, low high-density lipoprotein, 
elevated triglycerides and abnormal fasting glucose and often includes insulin 
resistance, hyperinsulinemia and dyslipidemia. There are different definitions of the 
syndrome, so there are different measures of its prevalence in population, ranging from 
1% to 30%. In Italy the metabolic syndrome affects 25% of and 27% of women, 
equivalent to about 14 million people [229]. 
Obesity is a medical condition in which excess body fat has accumulated to the extent 
that it may have a negative effect on health, leading to reduced life expectancy and/or 
increased health problems [230]. People are considered obese when their body mass 
index (BMI)  a measurement obtained by dividing a person's weight by the square of 
the person's height, exceeds 30 kg/m2. Authorities view it as one of the most serious 
public health problems of the 21st century [231]. Its prevalence is rising dramatically 
in both wealthy and poor countries, indeed worldwide obesity has nearly doubled since 
1980. In the 2008 the WHO estimates that 1.4 billion adults are overweight (35%of 
world population). Of these 500 million adults (greater than 10%) are obese, with 
higher rates among women than men [232]. 
Type II diabetes is a pathology characterized by chronic hyperglycemia in the context 
of insulin resistance, hyperinsulinemia and relative loss of -cellular mass. This is in 
contrast to diabetes mellitus type 1, in which there is an absolute lack of insulin due to 
breakdown of islet cells in the pancreas [233].  Type 2 diabetes makes up about 90% 
of cases of diabetes, with the other 10% due primarily to diabetes mellitus type 1 and 
gestational diabetes. Its prevalence, and related mortality, are rising, so that WHO 
recognize the diabetes as a global epidemic. Actually, there are approximately 285 
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million people with diabetes (6% world population) and it estimates that there will be 
600 million in 2030. In Europe, the diabetes causes the 10% of deaths in people ranging 
40 to 60 years [234].  
These metabolic disorders are three distinct pathological or sub-pathological 
conditions deeply interrelated. The conditions comprising the metabolic syndrome 
constitute major risk factors for type 2 diabetes; conversely, obesity is a risk factor for 
occurrence of the metabolic syndrome and diabetes. The metabolic syndrome is often 
defined as a pre-diabetic state. In effect, normo-glycemic subjects with metabolic 
syndrome present a 5-fold increased risk in diabetes developing [235], whereas in 
subjects with impaired fasting glucose and/or impaired glucose tolerance there is an 
additional 5-7 fold risk increase [236].  
Causal relationships between the metabolic syndrome, obesity and diabetes are 
controversial; however, these three disorders share risk factors, most of their etiology 
and many related health issues. Furthermore, they are related to glucose metabolism 
and to its control by the endocrine system and endocrine organs. 
The theory that environmental chemicals could explain a global metabolic disorders 
epidemic was proposed in 2002 [237]. The commonly held causes, overeating and lack 
of exercise, were considered insufficient to explain the observed increases in these 
debases rates. The chemical causation hypothesis was supported by the rapid onset of 
the increases, which appeared unlikely to be explained by genetic causes. Moreover, 
recent experimental studies have suggested that BPA affects glucose metabolism 
through diverse mechanisms including insulin resistance, pancreatic -cell 
dysfunction, adipogenesis, inflammation and oxidative stress, which presumed a 
plausible connections between BPA and diabetes [123], [238]. Indeed, It has been 
reported that higher BPA exposure, reflected in higher urinary concentrations of BPA 
recorded in the general adult population of the United States (1455 adults aged 18 
through 74 years), may be associated with diabetes [222]. More recently Shankar and 
Teppala (2011) and Silver et al. (2011) found the same conclusion in a representative 
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sample of U.S. adult cohort [239], [240]. A positive association between urinary BPA 
levels and pre-diabetes in 3516 subjects free of diabetes risk factors (body mass index, 
alcohol intake, blood pressure and serum cholesterol) has been reported. In subgroup 
analysis, this association was stronger among women and obese subjects [241]. 
Experimental evidences of BPA involvement in endocrine disruption of energy 
metabolism control, specifically in the disruption of endocrine pancreas function, are 
further discussed in sections below.  
 
1.3.1 The Pancreas  
The most important organ that control the glucose metabolism is the endocrine 
pancreas. 
The pancreas is both an exocrine and endocrine gland, it lies behind the peritoneum 
between the greater curvature of the stomach and the duodenum. It is a 15 cm long 
elongated structure and weighs approximately 85 to 100g. The exocrine portion 
consists of acini, which produce pancreatic juice, and a duct system that carries the 
pancreatic juice to the small intestine and the endocrine portion, consisting of 
pancreatic islets that are able to produce hormones that enter the circulatory system. 
The pancreatic islets are dispersed among the ducts and acini of the pancreas, with 
quantities ranging from 500,000 to 1 million, are able to secrete at least five hormones 
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and paracrine products, the most important of which are insulin, glucagon, and 
somatostatin [242].  
 
1.3.1.1 Islets of Langerhans  
The islets of Langerhans or pancreatic islets are scattered throughout the pancreas and 
constitute about 1%-2% of the pancreas. They contain several different cell types – 
including endocrine cells, endothelial cells, nerves and fibroblasts – a range in size 
from just a few islet cells to complex several thousand islet cells with a diameter up to 
300-400 μm. Each islet containing between 1000 and 3000 cells and contain insulin-
producing -cells, glucagon-producing -cells, somatostatin-producing δ-cells, 
pancreatic polypeptide-producing PP cells and ghrelin-producing epsilon cells [243].  
The main function of pancreatic β-cells is the biosynthesis and release of insulin, which 
is controlled by many signaling molecules including neurotransmitters, hormones and 
nutrients, among which glucose is the most important. Indeed β-cells function as 
glucose sensors with the crucial task of precisely adjusting insulin release to blood 
glucose levels, a process in which mitochondria play a central role. Altered nutrient 
Fig. 5 Simplified mechanism of the role and targets of insulin. [242] 
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storage and usage, hyperglycemia, and ultimately diabetes, appear when loss or 
dysfunction of the β-cells fall below a critical threshold [244][245].  
 
1.3.1.2 Animal model – the mouse  
In the mouse the pancreas is described as a diffuse pink gland located between stomach, 
duodenum and colon. It extends posteriorly in the duodenal loop, lying close to the 
mesenteric attachment. It is divided into irregular lobes and lobules. Several excretory 
ducts are present, some joining the bile duct where this crosses the pancreas before 
entering the duodenum. It is both an exocrine and endocrine gland, the first is a 
complex tubulealveolar gland lacking a connective tissue capsule but surrounded by 
loose vascular connective tissue of the mesentery and separated into lobes and lobules 
by septa of loose fibroelastic tissue. The endocrine portions is constituted by the islets 
of Langerhans, are always closely associated with the septal ducts and blood vessels. 
The percentage of the different cell subpopulations and the islet cytoarchitecture vary 
between species. In rodent islets, β-cells are the most abundant, 60–80% of the total 
number of cells and α-cells constitute 15–20%; in human islets the proportion varies, 
with the percentage of α-cells being higher (35–45%) and the β-cell percentage lower 
(55–65%). In humans α and β-cells are distributed evenly throughout the islet, 
suggesting that paracrine interactions between both types of cells may be vital, on the 
Fig. 6 Structure and morphology of the pancreatic islet. [242] 
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other hand in rodents β-cells constitute the core of the islets while non β-cells are 
distributed in the periphery [244][246]. 
 
1.3.2 Regulation of Blood Glucose by insulin  
The regulation of blood glucose levels requires insulin. Blood glucose levels can 
increase dramatically when too little insulin is secreted or when insulin receptors do 
not respond to it; consequently the pancreas is a vital organ for regulating glucose 
metabolism in the body.  The pancreatic -cells express the glucose receptors GLUT-
1 and GLUT-2, the first is more expressed in human while the second in rodents. 
Glucose is transported into β-cells, induced by the increase of plasma glucose levels 
and leads to insulin exocytosis, which manipulates the glucose levels [247]. The 
combination of glucose receptors, transports and phosphorylation proteins forms the “ 
glucosensor unit” that controls with feedback mechanism the maximum secretory 
response and the expression of GLUTs on the plasma membrane.  
 
Fig. 7 Representations of pancreatic islets  
glucose sensor unit. 
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The secretory response of β-cells depends on their electrical activity. The β-cell 
membrane contains specific transporters for glucose, which promote its entering into 
the cell by facilitated diffusion. Once inside the cell, it is phosphorylated to glucose-6-
phosphate by glucokinase, thereby initiating glycolysis and, subsequently, oxidized. 
Thereafter, mitochondrial metabolism generates ATP, one of the products of this 
oxidation step, which appears to be the key factor that regulates insulin secretion. K+ 
channels in the β-cell membrane are regulated by changes in ATP levels, when there 
is its increase (inside the β cell) the K+ channels close depolarizing the β-cell 
membrane. When depolarization occurs, membrane bound Ca2+ channels open and, 
subsequently, Ca2+ flows into the β cell. Then, the increases in intracellular Ca2+ 
concentration cause exocytosis of the insulin-containing secretory granules with the 
insulin being secreted into pancreatic venous blood and, then, delivered to the systemic 
circulation. This process is responsible of the short-term insulinic response (10 
minutes) that lead to exocytosis of ready releasable granules bound to the membrane. 
When there is a persistent glucose stimulus, additional signals are necessary to produce 
a sustained secretion of insulin. They participate in the amplifying pathway formerly 
referred to as the K+-ATP-channel-independent stimulation of insulin secretion.  
 
Fig. 8 Proximal and distal events that leads to insulin release 
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In contrast to the transient secretion induced by Ca2+ raising agents, the sustained 
insulin release depends on the generation of metabolic factors. This kind of insulinic 
response is more slow and progressive and can be induced only by high levels 
glycaemia persistent for long time [244], [248].  
 
1.3.3 - Mitochondria  
Mitochondria are key organelles that generate the largest part of cellular ATP and 
represent the central crossroad of metabolic pathways [248]. The metabolic profiling 
of β-cell identified mitochondria as key components for their function, as sensors and 
as generators of metabolic signals controlling insulin secretion [248]. In most tissues, 
cytosolic conversion of pyruvate to lactate by lactate-dehydrogenase ensures the 
NADH oxidation, however in β-cells this task is performed mainly through 
mitochondrial NADH shuttles, transferring glycolysis-derived electrons to 
mitochondria. This favors the transfer of pyruvate into the mitochondria, which is 
followed by a catabolism of glucose-derived pyruvate that induces mitochondrial 
activation and subsequently generation of ATP [245].  
A unifying theme is that production of reactive oxygen species (ROS) induced by 
metabolic stress represents a common pathway of injury in the cascade of events that 
ultimately results in β-cell failure [249]. Indeed, mitochondrial electron transport chain 
is the major site of ROS production within the cell. ROS formation is coupled with this 
electron transportation as a by-product of normal mitochondrial respiration through the 
one-electron reduction of molecular oxygen; furthermore mitochondria are also one of 
the primary targets of ROS. The mitochondrial genome is vulnerable to oxidative stress 
and consecutive susceptible to damages too more extent than nuclear DNA, due to the 
lack of protective histones and low repair mechanisms [248], [249]. Short transient 
exposure to oxidative stress is sufficient to impair glucose-stimulated insulin secretion 
in pancreatic islets. ROS may affect insulin-secreting cells, resulting in mitochondrial 
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inactivation, thereby interrupting transduction of signals and, as such, affecting insulin 
secretion. It was observed that one single acute oxidative stress may induce β-cell 
dysfunction, in a lasting over days manner, a fact that can be explained by persistent 
damages in mitochondrial components, accompanied by subsequent generation of 
endogenous ROS of mitochondrial origin [245], [248]. 
 
1.3.4 Role of Estrogens in Glucose Metabolism 
The (xeno)estrogens can modulate the energy balance influencing the activity of 
estrogens responsive endocrine organs that play a role in metabolism.  
They are part of the refined mechanism that enables the organism to adjust the 
metabolism to different energy needs. For example, the estrogens increase the 
glycaemia and the glucose usage during pregnancy. Nevertheless, inappropriate levels 
of estrogens, even in addition with xenoestrogens can disrupt this fragile endocrine 
control leading to pathological consequence (Fig. 10). 
 
Fig. 9 Action of excessive insulin signaling in different tissues. [244] 
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The involvement of estrogens in energy balance has been confirmed in studies on their 
receptors. ER- knockout as well as aromatase knockout (ArKO) mice are obese and 
insulin resistant [250][251]. This insulin-resistant state may be caused by the action of 
ER-, since this receptor is related to glucose metabolism in different tissues including 
skeletal muscle, adipose tissue, liver, brain and endocrine pancreas [252]. 
ER-modulates the GLUT4 expression in skeletal muscle and its transcript is 
extremely reduced in ER-−/− mice [253]. The ER-is also involved in modulating 
hepatic insulin sensitivity. Actually, ER-−/− mice have severe hepatic insulin 
resistance as well as a concomitant alteration of glucose uptake by skeletal muscle 
[254]. Additionally, estrogens control the distribution of body fat and adipose tissue 
metabolism, involving both ER-and ER- [255][256][257]. Indeed, it is known that 
estrogens can regulate the amount of white adipose tissue (WAT) in females and males. 
It has been demonstrated that the absence of ER- produces adipocyte hyperplasia and 
hypertrophy in WAT and is accompanied by insulin resistance and glucose intolerance 
[255][258].  
In the brain, the disruption of the ER-in the ventromedial nucleus of the 
hypothalamus leads to weight gain, increased visceral adiposity, hyperphagia, 
hyperglycaemia and impaired energy expenditure in female mice .  
The role of ERs in the physiology of the endocrine pancreas is still greatly 
undetermined. Plasma insulin levels are increased in pregnant rats in response to 
increased levels of sex steroids [252]. E2 at concentrations comparable to those in 
pregnancy enhances insulin secretion in perfused rat pancreas [259]. In humans, E2 
reverses the effect of menopause on glucose and insulin metabolism, resulting in 
increased pancreatic insulin secretion as well as improved insulin resistance [260], 
[261]. In mice, E2 acting partly through ER- protects pancreatic  cells from 
apoptosis induced by oxidative stress [262]. In in vitro studies on murine pancreatic 
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islet treatment with low doses of E2 increases pancreatic insulin expression, content 
and secretion through ER- [263].  
The novel membrane bound estrogen receptor is responsible for the rapid 
insulinotropic effect of E2 when applied at physiological concentrations, both in vitro 
and in vivo [264]. Once bound to its membrane receptor, estrogen triggers the synthesis 
of cGMP, which in turn activates protein kinase G (PKG). The ATP-dependent 
potassium channels (KATP), then, close in a PKG-dependent manner causing the 
plasma membrane depolarization and enhancing [Ca2+] signals [265]. As a result, 
insulin secretion is increased [266]. This receptor, activated by E2, abolishes glucagon 
release inhibiting [Ca2+] oscillations induced at low glucose concentrations [267]. 
Moreover, the increase of [Ca2+] by E2 in  cells is involved in the rapid activation of 
the transcription factor CREB, transforming an extranuclear initiated signal into a 
nuclear response [268].  
  
 
Fig. 10 Estrogen Receptors role in glucose homeostasis. 
[252] 
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Although estrogens receptors represent the main link between estrogens and 
metabolism, other feasible players currently emerging are liver X receptors (LXRs). 
LXRs are well recognized as important regulators of cholesterol homeostasis as well 
as modulators of lipid and carbohydrate metabolism. It is already known that estrogens 
can regulate LXRs in metabolic tissues [296]. In the liver, the activation of LXRs leads 
to the suppression of the gluconeogenic program. In white adipose tissue, the 
expression of GLUT4, which promotes glucose uptake, is upregulated after LXR 
activation . Besides its action on peripheral tissues, a novel role for LXR in the pancreas 
has recently been described. The LXR agonist T09011317 increase glucose dependent 
insulin secretion. On the other hand, the absence of LXR in mice leads to glucose 
intolerance and to an accumulation of lipid droplets in pancreatic islets [252].  
1.3.5 BPA - Metabolism Effects  
The BPA exerts its main effects on energy metabolism influencing the activity of white 
adipose tissue (WAT) and endocrine pancreas. BPA has many effects on WAT ranging 
from alteration of inflammatory cytokines and adiponectin release to lipid 
accumulation and changes of proteins [108], [269]–[271]. The adiponectin is a 
hormone produced by adipocytes that has different effect depending on the receptors 
bound, AdipoR1 or AdipoR2 [272]. It increases the fat acids oxidation and glucose 
metabolism in the skeletal muscle and reduces the hepatic gluconeogenesis enhancing 
the insulin sensibility [273]. Specifically, BPA inhibited adiponectin secretion from 
human adipose explants with a U-shaped NMDR curve: at concentrations of 1x10-10 M 
and 1x10-9 M inhibited the release, whereas doses of 1x10-8 M and 1x10-7 M were 
indistinguishable from unexposed controls [113]. Furthermore, higher concentrations 
of BPA (1x10-6 M) are able to stimulate IL-6 and TNFα release, two inflammatory 
cytokines. considering that low circulating adiponectin levels and elevated 
inflammatory cytokines are strongly associated with increased risks of obesity-related 
diseases, these data suggest a that BPA can be considered an obsogen [108]. It is also 
described that BPA is able to enter fibroblasts in the differentiation process and to 
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enhance the adipocyte conversion in combination with insulin suggesting that in vivo 
prolonged exposure to BPA might increase body fat mass and as such be involved the 
development of obesity [274].  
Several experimental studies, in vitro and in vivo, shown that BPA is able to influence 
the pancreatic islet function. Nadal et al. demonstrated in vitro on isolated islet that low 
doses of BPA (ranging from 1x10-10 to 1x10-6M) are equal to E2 in provoking increase 
of islet insulin content and release, as well as in increase of the insulin gene expression 
in an inverted U-shape dose response manner. This effect is mediated by ERs, as it is 
blocked by the co-incubation with the well-known ERs antagonist ICI 182,780[263], 
[264].  
Moreover, BPA has been shown to bind to both mER and GPR30 in -islet. Several 
studies have determined that these membrane-bound receptors are capable of non-
genomic steroid actions [113], [252], [268]. With the same mechanism previously 
described, low concentrations of BPA (1x10-10, 1x10-9M) induce the closure of K+-
ATP dependent channels, the increase of intracellular [Ca2+] and insulin release. The 
increase of intracellular Ca2+ leads also to activation of CREB, an ubiquitous 
transcription factor, that has many target gene among the others the insulin gene [268]. 
These results were confirmed by in vivo studies on mice. The administration of low 
doses of E2 in or BPA (10 or 100 ug/kg) induce a rapid (30 minutes) increase of insulin 
secretion ERs independent, accompanied by a glycaemia reduction. More prolonged 
treatment (4 days) increase the insulin content and release, raise the insulin response to 
high levels of blood glucose and alter the glycemic and insulinic curve after IGTT 
(intraperitoneal glucose tolerance test) and ITT (insulin tolerance test). The results of 
these three works (reviewed in [238]) suggest a potential role of BPA in establishment 
of hyperinsulinemia, insulin resistance and impaired glucose tolerance. To confirm 
this, more prolonged exposures, lasting 8 days to 10 weeks, were tested and verified to 
alter blood glucose and insulin levels, glucose and insulin tolerance, food intake, 
triglyceride levels, and responses to sugar challenges [220], [275], [276]. 
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More recently a new link between BPA and metabolic disorders that involve the 
demonstrated ability of BPA to generate oxidative stress and inflammation [277] has 
been proposed. This hypothesis suggests that BPA, through these mechanisms, 
promotes insulin resistance and alters adipocyte activity and proliferation. 
Furthermore, it would also be able to impair pancreatic islet function and vitality 
damaging their mitochondrial activity.  
A study on effect of BPA on mitochondrial activity, oxidization and inflammation was 
conducted on HepG2 cells, an hepatic cell line containing the entire battery of 
detoxification enzymes, with concentration of BPA ranging from 1x10-12 to 2x10-4 M 
[218]. The results shown that BPA induce a mitochondria-dependent ROS (reactive 
oxygen species) generation and lipoperoxidation, which led to a late cytosolic oxidative 
stress, sustained in time (72h) and showing a non-monotonic dose-response pattern (an 
inverted U-shape dose response). Mitochondria-related oxidative stress mainly results 
from a dysfunction of the respiratory chain [278]. In fact, the cells exposed to BPA 
shown also a membrane hyperpolarization. This state is usually associated with ROS 
generation, due to a poor electron flux leading to a direct reaction with oxygen [279]. 
It is worth noting that the increase of ROS associated with the increase of membrane 
potential is relevant for liver cell injury [278].  
A recent study conducted on rat insulinoma cell line (INS-1) [280] shown that low dose 
of BPA (ranging from 2x10-9 to 2x10-6M) induce changes in mitochondrial mass, 
morphology, membrane depolarization and it reduces the ATP production. Moreover, 
exposure results in a dose dependent increase in the proportion of early apoptotic and 
apoptotic cells. A higher expression of BAX gene was observed as well as a reduced 
expression of BCL-2. The mitochondrial and cytosolic fractions were prepared from 
INS-1 cells to investigate whether the release of cytochrome c was involved in the 
apoptotic process induced by BPA. Indeed, cytochrome c amount was reduced with 
increasing BPA concentrations in isolated mitochondria but significantly elevated in 
the cytosolic fractions in INS-1. Thus, BPA promoted the translocation of cytochrome 
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c from the mitochondria into the cytosol in INS-1 cells. Another study, on ex vivo rat 
pancreatic islets, partially confirm these results [281] reporting, also, mitochondrial 
abnormalities at higher BPA concentrations (2.5x10-5M). Recently, it has been reported 
that oxidativestress induced by BPA can accelerate toxic aggregation of human 
isletamyloid polypeptide (hIAPP, a hormone synthesized and secreted bythe 
pancreatic β-cells) leading to β-cell death [111]. 
Collectively, all these results indicate that low doses of BPA can adversely affect 
metabolic pathways that are revealed in vitro cultured pancreatic islets and in vivo in 
rodents, suggesting that the associations between BPA exposures and metabolic 
disorders, in some human populations, can be obvious adverse endpoint. 
1.4 Thesis Aim 
The widespread exposure to BPA and the already proven effects on the human 
organism are of concern. BPA is considered as an EDC able to play a role in the onset 
of metabolic disorders  as acting on multiple organs and tissues involved in glucose 
homeostasis.  
The overall objective of this study is to identify the effects of BPA on ex vivo murine 
pancreatic islets and dissect its endocrine disruption mechanism in the regulation of 
islets function using a toxicogenomic approach. We chose to study the effects of three 
different concentrations of BPA, 1x10-4M, known to be cytotoxic, 1x10-6M and 1x10-
9M to mimic worker and worldwide population exposure, respectively. We focused on 
the effects of 1x10-9 M BPA, as it can be considered the environmental concentration. 
We specifically aim to evaluate: 
 the influence on the viability of the islet cells   
 the alterations inducted in the trascriptome  
 the specific cellular functions impaired 
 the pathways involved in endocrine disruption 
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2 Materials and Methods 
2.1 Mice  
C57/B6 male mice (Biogem s.c.a.r.l., Animal Facility [Biogem AMF], Ariano Irpino 
[AV], Italy) were used given the animal experimentation background, more 
specifically the existent data related to the pancreatic influence from BPA. Mice were 
housed in polysulfone cages with ad libitum access to water and normal diet under 
specific pathogen-free facility at 22°C  2° temperature and 55%  15% relative 
humidity with 12h light:12h darkness cycle and 18  2 changes of air per hour. All 
experimental procedures on animal were executed in Biogem AMF rooms. The 
procedures, equipment and environments used in this study comply with the 
Legislative Decree of 27 January 1992 No. 116, which transposes the European 
Commission's Directive 86/609/EEC concerning the protection of animals used for 
experimental and other scientific purposes. All aspects of the study regarding animal 
welfare were approved by the Ethics Committee of the Biogem scar.l. and the Ministry 
of Health. 
 
2.2 Isolation, purification and culture of mouse pancreatic islets 
Primary cultures of mouse β-Islets were prepared following a Gotoh et al. modified 
protocol [282]. Briefly, after mouse sacrifice (CO2 inhalation), the pancreas was 
exposed and injected with 3mls of collagenase solution (0.8mg/ml of Collagenase P 
[Roche Dignostic GmbH] in HBSS [Sigma-Aldrich]) (Fig. 12). Then, the pancreas was 
excised and digested by 37.7 °C incubation for 12 minutes. After 2 washing step, the 
islets were purified by differential centrifugation on Histopaque 1077 (Sigma-Aldrich) 
and HBSS density gradient (Fig. 12, E). The islet yield and quality was checked on an 
inverted microscope and the islets were handpicked and cultured at 37°C with 5% CO2. 
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In RPMI 1640 (Sigma-Aldrich) + 10% Fetal Bovine Serum (FBS, Sigma-Aldrich) + 
11mM glucose (Sigma-Aldrich) + 1% Pen/Strep (Sigma-Aldrich). 250-300 islets per 
6cm dish with 3mls of media were used, in order to avoid stressing them. When 
indicated, isolated islets were treated with 1x10-4, 1x10-6, 1x10-9 M BPA, E2, 50mM, 
25 mM glucose, 3mM N-Acetyl-l-cysteine, 10M BMS 345541, 10M LY294002, 
10M ICI182780, or vehicle (DMSO, Sigma-Aldrich) and incubated for 24h, 48h or 7 
days. 
 
2.3 Islets disaggregation 
Dispersion of cells with Ca2+-free medium was done immediately after the isolation 
of islets. Islets were incubated for 5 minutes at 37°C in 0.25% trypsin-EDTA (Sigma-
Aldrich), then washed and resuspended in culture medium and plated. 
2.4 Isolation, purification and culture of mouse hepatocytes 
Primary hepatocytes were obtained by collagenase perfusion of anesthetized mice. 
After anesthesia and laparotomy a PE10 catheter was introduced in portal vein. The 
 
Fig.11 Murine pancreas 
ex vivo perfusion and 
islets isolation:  
(A, B, C) pancreas 
exposition and injection; 
(D, E) pancreas removal; 
(F): Islets gradient 
purification. 
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liver was perfused with a pre-digestion solution (HBSS w/o Mg and Ca + 0.5mM 
EGTA + 25mM Hepes + 1% Pen/Strep[Sigma-Aldrich], pH 7.4) pre-warmed to 37 ºC 
for 10 min at the rate of 5 mL/min, afterwards perfused with pre-warmed digestion 
solution (William’s E Medium + 15mM Hepes + 1% Pen/Strep + 0.32 mg/ml 
Collagenase type IV [Sigma-Aldrich], pH 7.4) at the same rate for 10 minutes. 
The digested liver was excised and hepatocytes were released with gentle shaking of 
the digested liver into 15 ml of hepatocyte isolation medium (William’s E + 4% FBS 
+ 1% Pen/Strep [Sigma-Aldrich]). The digested was filtered (70mM) and twice 
washed. In order to access the quality of the perfusion the cell viability was assessed 
via trypan blue staining and then the cells were plated in collagen type I (Sigma-
Aldrich) coated dishes with hepatocyte isolation medium. After allowing the cells to 
attach for approximately 6 hours at 37°C, they were washed once with PBS and the 
hepatocyte isolation medium was replaced with hepatocyte growth medium (William’s 
E + 4% heat inactivated FBS + 1% Pen/Strep + 50ng/ml Epidermal Growth Factor + 
1mg/ml insulin + 10mg/ml Transferrin + 1.3 mg/ml Hydrocortisone [Sigma-Aldrich]). 
When indicated, hepatocyte were treated with 1x10-9 M BPA, or vehicle (DMSO, 
Sigma-Aldrich) and incubated for 24h, 48h. No longer treatments were performed due 
to in vitro mesenchymal transition of the hepatocytes. 
2.5 MTT assay 
In order to access the cell proliferation, cell viability, and cytotoxicity the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed 
on hepatocytes or dispersed islets in a 96-well plates. The MTT reagent in PBS was 
added to the cells (final concentration of 0.5 mg/ml) and the cultures were incubated 
for 4 h at 37°C. The reaction was stopped removing the reagent and adding 100 µl of 
acidified isopropanol (0,04% HCl) to each well. To dissolve the tetrazolium crystals 
the plates were mixed on a plate shaker for 10 min at room temperature Absorbance at 
595 nm was read in EnVision™ 2103 Multilabel Reader (Perkin Elmer). 
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2.6 RNA Extraction 
RNA was extracted from isolated islets or hepatocytes using a commercial kit (Trizol 
reagent, Invitrogen) according to the manufacturer’s instructions. A further step of 
RNA purification was made with a phenol-chloroform procedure. The RNA 
concentration and purity was determined with the NanoDrop spectrophotometer ND-
1000. For qRT-PCR, 1 mg of total RNA was reverse-transcribed by using the 
QuantiTect Reverse Transcription Kit (Qiagen) in a total volume of 20ml, according 
to the manufacturer’s instructions. 
2.7 Microarray 
cRNA was generated by using the Affymetrix One-Cycle Target Labeling and Control 
Reagent kit (Affymetrix Inc), according to the manufacturer’s instructions, starting 
from 5 µg of total RNA. Biotinylated cRNA was hybridized to the Mouse MOE 430 
2.0 Genome Arrays (Affymetrix). Chips were washed and scanned on the Affymetrix 
Complete GeneChip System, generating digitized image data (DAT) files.The datasets 
obtained were analyzed with GeneSpring GX 12 Software (Agilent Technologies). 
Robust multichip average (RMA) algorithm [283] was used for summarization and 
normalization. Hybridization quality was assessed by spiked-in controls. Principal 
Component Analysis (PCA) was performed to check data quality that resulted adequate 
for all samples. Transcripts were filtered by their signal intensity values, selecting 
transcripts with intensity values between 20 and 100 percentile in at least 1 out of each 
set samples for differential analysis.   
Differentially expressed transcripts between exposed islets vs controls were filtered for 
absolute fold-change ≥ 1.5 and corrected p-value ≤ 0.05. Statistical analysis was 
performed using Oneway ANOVA adjusted for multiple comparison by the Benjamini-
Hochberg method. 
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Functional annotation for differentially expressed transcripts was performed using 
Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com), a web-based tool for 
the identification of biological functions as well as canonical pathways that are most 
significant to the dataset. Fisher Exact test was used to calculate the p-value 
determining the likelihood that the association between the set of focus genes in the 
dataset and a given process or pathway is due to chance alone. Corrected p-value 
calculation (based on the Benjamini-Hochberg method) controlled the error rate in 
analysis results and focus in on the most significant biological functions associated 
with DEG. 
2.8 Real Time PCRs 
The qRT-PCR experiments were conducted using Applied Biosystem 7300 Real-Time 
PCR System and Power SYBR Green Master Mix (Applied Biosystems). Result 
analysis was performed following real-time relative quantization guidelines through 
the relative standard curve method as suggested by Applied Biosystems. Briefly, the 
amplification efficiency of each primer pair was calculated from triplicate relative 
standard curves for each primer pair using the equation E = 10 −1/slope and then used 
to convert Ct values obtained from each reaction into relative-expression units. Data 
obtained in this way were then normalized on the relative expression of three reference 
genes (Gapdh, Tubulin and b-2-microglobulin [B2M]) [284]. Primers were designed 
using NCBI Primer Blast tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
Primer sequences used in the study are listed in Table 2. 
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TABLE 2 Primers sequences 
Gene Forward primer Reverse primer 
Bax ACAGATCATGAAGACAGGGG CAAAGTAGAAGAGGGCAACC 
Sod2 CGTGAACAATCTCAACGCCACCGA CCTCCAGCAACTCTCCTTTGGGTT 
Uqrcb GCGGGCCGATCTGCTGTTTC GCCTCATAGTCAGGTCCAGGGCT 
Gpx3 AAACAGGAGCCAGGCGAGAACT CCCGTTCACATCTCCTTTCTCAAA 
Ttc35 AGCAGGTCATGATTGCAGCCCT ACGCTTTCTGGCAGCAGTGTT 
Vapa GAGATGTGTGTTTGAAATGCCGA GGTCCGTCTTGTTTGGATGC 
Ndufs4 TGGCTACAGCTGCCGTTTCCG GGTCAGCGGTTGATGCCCAA 
Zfand2a ACCCGTGAGTGCCAGGTGAT AACAGTGCTTCCCCAAGTCAGGA 
Iars GACTTGGAGGAGGTAGTGTGC GATGGGATGGTCAGGTGGTC 
Atp1b1 CTTCCGTCCTAATGACCCCA TGATTGATGTCGCCCCGTTC 
Atp6v1f ATCGAAGACACTTTCAGGCAA ATGCTCCTTGGACGGGATCT 
Gapdh ACCACAGTCCATGCCATCAC CACCACCCTGTTGCTGTAGCC 
Tub CAACACCTTCTTCAGTGAGACAGG TACATGATCTCCTTGCCAATGGT 
B2M CCGAACATACTGAACTGCTA TGCTATTTCTTTCTGCGTGC 
 
2.9 ATPlite assay 
In order to assess the cells ATP production a luminescence assay based on firefly 
luciferase (ATPliteTM assay, Perkin Helmer) was performed on hepatocytes or 
dispersed islets in 96-well black plates according to manufacturer’s instructions. The 
ATPLite assay involved adding a 50 μl lysis solution to each well of a 96-well plate 
followed by a 50 μl substrate solution. The plates were dark-adapted, and luminescence 
was measured in Orion II microplate luminometer (Berthold Detection Systems 
GmbH) giving comparative adenosine triphosphate levels. 
48 
 
2.10 TUNEL assay 
Apoptotic cells were visualized by using a terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL) assay kit (In Situ Cell Death Kit, Fluorescein, Roche 
Applied Science) according to manufacturer’s instructions. In brief, after islets 
dispersion, the cells were plated in an 8-well slide chamber and treated for 48h with 
diverse concentration of BPA or with only vehicle for three controls, untreated (C), 
Negative Control (CN), and Positive Control (CP). At the end of the treatment the cells 
were fixed with 4% paraformaldehyde and permeabilized with 0.1% sodium citrate and 
0.1% Triton X-100. Then, the samples were incubated in the TUNEL reaction mixture 
for 1 h at 37 °C in dark. For CP, the cells were previously treated with DNase I for 10 
min at 15 to 25ºC, and for CN, the cells were incubated with label solution without 
terminal transferase, instead of the TUNEL reaction mixture. After the reaction was 
completed, the slides were rinsed with PBS, counterstained with a 1μg/mL DAPI 
solution and mounted. The number of apoptotic nuclei and total number of nuclei were 
determined under a fluorescence microscope  
2.11 Statistical and bioinformatics analyses 
The statistical analyses have been performed with Student’s t test using Office Excel 
for Window, unless otherwise indicated. In all cases, probability p-values below 0.05 
were considered significant. Data from at least three independent experiments were 
considered for the statistical analysis. To retrieve the hypothetical transcriptional 
factors binding sites in the genes promoter, their sequence ranging from −1000/+50 bp 
has been loaded in Genomatix suite software (Genomatix Software GmbH, 
http://www.genomatix.de/) and analyzed at the relative profile score of the 80% [285].  
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3 Results 
3.1 Low doses of BPA does not alter the murine pancreatic islets morphology 
To assess the influence of BPA on murine pancreatic islets vitality and morphology, 
after the isolation and plating they were treated, for 48 hours, with different doses of 
BPA, 1x10-4, 1x10-6, 1x10-9 M and to 5x10-2 M of glucose, as positive control. The 
exposure to BPA did not induce macroscopic changes in the morphology of the islets 
at the lower dose (1x10-9 M, Fig 12 D). The central necrotic core, typical of ex- vivo 
cultured islets, was clearly visible and border was clearly defined (Fig. 12 A and D). 
Nevertheless, at higher concentrations and in positive control this core was not visible, 
probably already expelled as the presence of large amount of debris near the islets 
suggests (Fig 12 B, C and E). Moreover, the morphology of these islets seems more 
granulated and less compact than the controls.  
 
Fig. 12 Morphology of pancreatic islets after 48h treatments with BPA at diverse 
concentrations. Representative images of pancreatic islets at 40x magnification. 
Islets were exposed to: vehicle only (DMSO) (A), 1x10-4M (B), 1x10-6 M (C), 1x10-
9M (D) BPA or 5x10-2M glucose (E). Red arrows show the ejected necrotic central 
core 
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3.2 BPA impairs murine pancreatic islet cells viability 
 
The MTT assay was used to investigate the effects of BPA at diverse concentrations 
on islet cells viability; treatment with to 5x10-2 M of glucose was used as positive 
control. The treatment was performed on disperses pancreatic islets and lasted 24h, 48h 
or 7 days. As it is visible in the Figure 13 A, BPA affected the viability of dispersed 
islets in a dose dependent manner. The concentration of 1x10-4 M had the strongest 
effect, completely comparable to that exerted by glucose 5x10-2 M. Treatment with 
BPA at 1x10-6 M had an intermediate effect while lowest concentration had a mild 
effect. Specifically, cells exposed to 1x10-6 and 1x10-9M BPA for 24 hours did not 
exhibit any significant change in viability, whereas at 1x10-4 M BPA and 5x10-2 M 
glucose cell viability was significantly decreased to 75 or 63%, of that observed in 
 
Fig. 13 Murine islets cell viability as determined by MTT assay. Islet cells were cultured in the 
presence or absence of 1x10-4 M, 1x10-6 M, 1x10-9 BPA or 5x10-2 M glucose for 24h (B), 48h 
(C),168h (D). (A) is a comparison of time response curve at diverse concentrations of BPA or 
glucose. Data are reported as fold change value calculated as ratio between average absorbance 
in control and treated cells as the mean ± standard deviation of at least three independent 
experiments.  
* p-value<0.05; **p-value<0.01; ***p-value<0.001 compared with untreated control cells 
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control, respectively (Fig. 13 B). When the incubation time was extended to 48 hours, 
1x10-4 M, 1x10-6 and 1x10-9 M BPA significantly reduced the viability of pancreatic 
cells to 61, 68, 79 % of that observed in unstimulated control cells (Fig. 13 C). After 7 
days treatment (Fig. 13 D), glucose and 1x10-4 M BPA strongly affected the viability 
(23 and 32%) and a further decrease was also observed for cells treated with 1x10-6 M 
BPA (55%). No further decrease (82%) was observed upon treatment with 1x10-9 M 
BPA .  
3.3 Microarray analysis: Low concentration of BPA alters murine pancreatic 
islets gene expressions 
As stated in literature, pancreatic islets exposure to BPA is associated with multiple 
effects. Therefore, we performed a gene expression profile analyses (microarray) to 
have a global look of the transcriptional responses of the islets to low dose BPA. The 
explanted islets were treated for 48 hours with 1x10-9 M BPA or with only vehicle.  
The RNA was purified and subjected to microarray analysis. To minimize the effects 
of inter-individual variations we organized a system of pools of pancreas and then of 
RNA, following the scheme in figure 14. The use of mice from an inbred strain and of 
the pool system allowed minimizing the number of required animals.  
 
Fig. 14 Pool system for microarray analysis. To minimize the effects of mice inter-individual 
variations, for each group, the islets from three pancreas were pooled, then re-divided in two 
parts for treatments. After collecting the two RNA for each group, treated and controls were 
pooled again and addressed to microarray analysis 
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The microarray data were analyzed using the GeneSpring Software. A Volcano Plot of 
the data obtained is reported in Figure 15 A; it is a representation of the differential 
gene expressions between the control and the treated conditions. The Volcano plot 
allows the visualization of the relationship between fold-change and statistical 
significance [286]. A change of at least 1,5 fold (up or down) threshold was considered 
meaningful for the experiment. Surprisingly, the analysis gave only a small group of 
29 Differential Expressed Genes (DEGs, green color) and all of them were down-
regulated. However, as visible in figure 15 A, the down-regulation was the general 
trend. Figure 15 B shows the heat map made from the analysis of the microarray data. 
The expression levels are represented by the pattern of colors as it is visible in the 
magnification done, where the genes having lower expression levels than the control 
samples, represented in green, are highlighted. 
 
Fig. 15 Transcriptome alteration of murine pancreatic islets after BPA exposure.  
(A): Volcano plots of microarray data in 48h 1x10-9M BPA treated islets compared to untreated 
control islets. The y-axis value is the negative logarithm base 10 of the corrected p value. A green 
horizontal line on the plot represents the user-defined significant threshold for p value. The x-
axis is shown as the logarithm base 2 of the fold change in expression level between treated and 
control. The vertical green lines on the plot represent the user defined thresholds for fold change. 
Green dots down-regulated genes. (B): HeatMap from the same microarray data. In the right, 
there is a representative magnification of the genes that were found to be deregulated. 
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The DEGs and their respective fold changes and p-values are listed in the Table 3. 
Given the referred threshold of 1.5 fold-change, 29 genes (or pseudogenes) were found 
differentially expressed. More precisely a fold change ranged from -1.50 and -2.30 was 
found. Some of these genes codify for mitochondrial localized proteins involved in 
respiratory chain, in ROS detoxification process or in generation of insulin exocytosis 
signal (ATP synthesis and membrane hyperpolarization). Moreover, there are also 
genes involved in more generic mechanisms of the cell, such as polymerases, ribosomal 
proteins and MAPK. 
TABLE 3: Differential Expressed Genes 
Gene symbol 
Fold 
change 
p-
value 
Genedescription 
Refseq  
acc. numb. 
Uqcrb -2,3 0,04 ubiquinol-cytochrome c reductase binding protein NM_026219 
Gpx3 -2,07 0,01 glutathione peroxidase 3 NM_001083929 
Ttc35 -1,91 0,02 tetratricopeptide repeat domain 35 NM_025736 
Alg3 -1,88 0,05 asparagine-linked glycosylation 3 homolog NM_145939 
Rpl23 -1,84 0,04 ribosomal protein L23 NM_022891 
Cript -1,84 0,02 cysteine-rich PDZ-binding protein NM_019936 
Ptplb -1,76 0,03 protein tyrosine phosphatase-like NM_023587 
Mat2a -1,75 0,02 methionine adenosyltransferase II, alpha NM_145569 
Zfand2a -1,73 0,05 zinc finger, AN1-type domain 2° NM_133349 
Snora23 -1,72 0,03 small nucleolar RNA, H/ACA box 23 NR_033336 
Ndufs4 -1,69 0,03 NADH dehydrogenase (ubiquinone) Fe-S protein 4 NM_010887 
Tm9sf3 -1,69 0,04 transmembrane 9 superfamily member 3 NM_133352 
BC031181 -1,67 0,04    
Mapk1ip1l -1,66 0,03 mitogen-activated protein kinase 1 interacting protein 1-like NM_178684 
Aff2 -1,66 0,01 AF4/FMR2 family, member 2 NM_008032 
Rpp38 -1,65 0,05 ribonuclease P/MRP 38 subunit (human) NM_001013376 
Atp1b1 -1,64 0,03 ATPase, Na+/K+ transporting, beta 1 polypeptide NM_009721 
Rps20 -1,62 0,01 ribosomal protein S20 NM_026147 
2900064A13Rik -1,58 0,03 RIKEN cDNA 2900064A13 gene  
Rps11 -1,57 0,04 ribosomal protein S11 NM_013725 
Iars -1,56 0,02 isoleucine-tRNA synthetase NM_172015 
Sod2 -1,55 0,04 superoxide dismutase 2, mitochondrial NM_013671 
MRF-1 -1,55 0,04 splicing factor, arginine/serine-rich 2 (SC-35) NM_011358 
Vapa -1,54 0,05 vesicle-associated membrane protein, associated protein A NM_013933 
BC056474 -1,54 0,04    
Atp6v1f -1,53 0,02 ATPase, H+ transporting, lysosomal V1 subunit F NM_025381 
Tm2d1 -1,53 0,04 TM2 domain containing 1 NM_053157 
Tmem167b -1,52 0,02 transmembrane protein 167B NM_026198 
Polr2f -1,51 0,03 polymerase (RNA) II (DNA directed) polypeptide F NM_027231 
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3.4 Microarray analysis: Low concentration of BPA impairs pancreatic murine 
islets mitochondrial functions 
Additionally, to identify if the deregulated genes were involved in any fundamentally 
and biologically specific disorders, we performed an IPA Canonical Pathway analysis 
using the list of DEGs. As expected, this analysis gave only two deregulated Canonical 
Pathways and both pertaining to mitochondrial function: oxidative phosphorylation 
and mitochondrial dysfunction (Fig. 16). 
  
3.5 Microarray validation: Low concentration of BPA alters genes involved in 
specific cell functions  
Microarray results can be influenced by each step of the complex assay, from array 
manufacturing to sample preparation (extraction, labeling and hybridization) and 
image analysis. So a validation of expression differences accomplished by an 
alternative method is required. Quantitative Real time PCR (qRT-PCR) was the 
strategy chosen to perform this validation since it is rapid and applicable to samples 
 
Fig. 16 IPA Analysis of DEGs. Most significant Canonical Pathways 
deregulated in pancreatic murine islets exposed to 1x10-9M BPA for 48h 
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with limited amount of RNA [287]. We analyzed the gene expression of 9 out of 29 
genes in a new experimental set. The genes were chosen according to properties or 
functions of the proteins for which they encode. Uqrcb (NM_026219) and Ndufs4 
(NM_010887) encode for protein involved in the electrons transport chain; they are 
sub-units of complex III and complex I, respectively [103][104]. Gpx3 
(NM_001083929) and Sod2 (NM_013671) encode well-known proteins involved in 
protection of the cell against free radicals. Gpx3 catalyzes the reduction of hydrogen 
peroxide, organic hydroperoxide, and lipid peroxides by reduced glutathione and 
functions in the protection of cells against oxidative damage [290]. Sod2 is a 
mitochondrial matrix enzyme that scavenges oxygen radicals produced by the 
extensive oxidation-reduction and electron transport reactions occurring in 
mitochondria [291]. Atp1b1 (NM_009721) encodes a beta subunit of the Na+/K+ 
ATPase pump that is involved in membrane depolarization and in the generation of 
exocytosis signal [292]. Atp6v1f (NM_013933) encodes a component of ATPase, 
which is able to generate ATP using the H+ gradient across the mitochondrial 
membrane [293]. Zfand2a (NM_133349) encodes the protein Airap that enhances the 
proteasome function during cell stress and is involved in disposal of protein aggregates 
[294]. Vapa (NM_013933) is a type IV membrane protein present in plasma membrane 
and intracellular vesicles or granules. It is involved in vesicle trafficking, membrane 
fusion and tight junction formation [295]. Iars (NM_172015) encode isoleucine-tRNA 
synthetase that catalyze the aminoacylation of tRNA by their cognate amino acid. 
Changes in the aminoacylation properties of tRNA-Ile (a loss of isoleucylation 
efficiency or acquisition of mischarging properties) have been associated to a glycogen 
and lipid accumulation and to decreased reactivity for cytochrome c oxidase in the 
muscle [296]. 
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To validate the microarray results, we prepared new sets of samples with the aim to 
analyze also the kinetic of the cellular level regulation of the above reported transcripts 
upon exposure to low dose of BPA. In the Figure 17 are represented the qRT-PCR 
results obtained using RNA prepared from islets treated with 1x10-9 M BPA at three 
different time-points of treatment, 24, 48 and 178 hours. The reported data confirmed 
their downregulation with significant p-values at 48 hours as resulted from microarray. 
Most of them had a gene expression inhibition equal or greater to that found with the 
analysis of microarray, ranging from fold change of  -1.56 to -1.78 (Atp6v1f, Gpx3, 
Sod2, Iars, Ndufs4 and  Uqcrb, Fig 17 A, B, C, and D), whereas 3 genes had a milder 
down-regulation (from -1.06 to -1.25, Atp1b1, Vapa, Zfand2a, Fig. 17 C and D). At 24 
 
Fig.17 Gene expression alteration of selcted genes in murine pancreatic islets as determined 
by qRT-PCR. Islets were cultured in presence or absence of 1x10-9 M BPA for 24 h, 48 h or 168 h. 
The selected DEGs are grouped by functional categories. ROS detoxification, Gpx3 and Sod2 (A). 
Respiratory chain subunits, Uqcrb and Ndufs4 (B) ATP-dependent pump subunits (C). Protein 
synthesis and degradation, Vapa, Iars, Zfand2a (D). Data are reported as fold change values 
calculated as ratio between average gene expression in control and treated cells. The qRT-PCR 
results are expressed as the mean ± standard deviation of at least three independent 
experiments.   
* p-value<0.05; **p-value<0.01; ***p-value<0.001 compared with untreated control cells 
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hours of treatment, 2 genes already are strongly downreguleted, over the cut-off of -
1.5 (Atp1b1 -1.96, Gpx3 -1.92, Fig 17 A and C). Furthermore, 2 genes had a milder 
downregulation (Ndufs4 -1.43, Vapa -1.33 , Fig. 17 B and D), whereas 5 genes had no 
significant expression inhibition (Sod2, Uqcrb, Atp6v1f, Iars, Zfand2a, Fig 17 A, B, C 
 
Fig. 18 Hepatocyte primary cultures and their gene expression alteration. 
A, B, C, D: Primary culture of murine liver cells. After 12 h of culture, parenchymal hepatocytes 
are attached to the dish’s surface, and showed typical hexagonal cobblestone-like morphology 
with one or two round nuclei (A, 20X magnification). After 24 h, they spread on the dish’s surface, 
establish intercellular contacts and maintain their morphology (B, 20X). After 48 h, they begin to 
assume a tapered shape but rounded nuclei are still visible (C, 10X). Parenchymal hepatocytes 
lost their epithelial cell morphology within 7 days in culture, and transformed into more flattened 
fibroblast-like cells (D, 10X). E: Albumin gene expression quantification as hepatocyte molecular 
marker by qRT-PCR. The data are reported as fold change values as ratio between average 
expression of albumin gene in MEFs and in diverse time cultured hepatocytes. F, G, H: expression 
alteration of selected genes in murine hepatocytes. Hepatocytes were cultured in presence or 
absence of 1x10-9M BPA for 24 h or 48 h. Data are reported as fold change values calculated as 
ratio between average gene expression in control and treated cells. The qRT-PCR results are 
expressed as the mean ± standard deviation of at least three independent experiments.  
* p-value<0.05; **p-value<0.01; ***p-value<0.001 compared with untreated control cells 
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and D ). After 7 days of treatment the number of genes that had a significantly gene 
expression inhibition was reduced (Gpx3, Vapa, Zfand2a). The most of them had no 
significant variation and one, Atp6v1f, had even a mild upregulation in gene 
expression. 
3.6 BPA has specific effects on murine pancreatic islets 
 
To ensure that the alteration of the transcriptome was a specific effect of BPA on 
pancreatic islets, we decided to check the gene expression of the same genes on cells 
from another organ involved in glucose homeostasis, primary ex vivo murine 
hepatocytes. An in vivo and in vitro study, using hepatocellular carcinoma cell line 
(Hep2G) and C57/b6 mice injected with low doses, showed that BPA could alter liver 
enzyme (AST and ALT) and cytokines release (TNF-and IL-6) [297]. In vivo data 
suggest that BPA is able to induce oxidative damage in liver after long and repeated 
exposure [298]. Moreover, another study demonstrated that BPA could alter the 
mitochondrial function in Hep2G cells enhancing ROS production [218]. The 
hepatocytes ware treated with 1x10-9 M BPA for 24h and 48h. The 168h treatment was 
not performed because of in vitro mesenchymal transition of ex vivo hepatocytes [299] 
(Fig. 18 A, B, C and D). This fibroblast-like conversion was confirmed comparing the 
mRNA levels of Albumin gene in mouse embryonic fibroblasts (MEFs) with those in 
hepatocytes after 24h, 48h and 168h in culture by a qRT-PCR. After 7 days, 
hepatocytes had an Albumin gene expression 6 times lesser than 24h and 48h cultured 
hepatocytes (Fig. 18 E). As is visible in figure 18 F, G and H, the DEGs found in 
murine pancreatic islets, in this system were very stable and did not appear to be 
influenced by 1x10-9 M BPA treatment neither at 24h nor at 48h, with the exception of 
Sod2 and Gpx3 genes at 24h that appeared upregulated and downregulated, 
respectively. Thus, this data suggest that the effects detected in pancreatic islets 
transcriptome are specific and that the alterations on liver function, especially those on 
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mitochondria, observed by others authors are dependent to other mechanisms of 
disruption. 
3.7 Low concentrations of BPA have no effect on ATP production 
 
Considering the role that some of the reported genes have to the ATP production 
[103][104][108], we performed experiments to have a direct measure of the ATP 
production. ATP intracellular level was determined by the ATPLiteTM (PerkinElmer) 
and treatment with to 5x10-2 M glucose was used as positive control. The dispersed 
pancreatic islets were treated with diverse concentrations of BPA for 24h, 48h or 168h. 
As expected, since this assay is directly linked to the number of viable cells, the results 
 
Fig. 19 Murine islets cell intracellular ATP concentration as determined by ATPlite assay. Islet 
cells were cultured in the presence or absence of 1x10-4 M, 1x10-6 M, 1x10-9 BPA or 5x10-2 M 
glucose for 24h (B), 48h (C),168h (D). (A) is a comparison of time response curve at diverse 
concentrations of BPA or glucose. The data are compared with previously reported MTT assay 
results. Data are reported as fold change value calculated as ratio between average luminescence 
in control and treated cells as the mean ± standard deviation of 3–6 replicates from at least three 
independent experiments.  
* p-value<0.05; **p-value<0.01; ***p-value<0.001 compared with untreated control cells 
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followed the same trend of those obtained with MTT assay, with a linear dose response 
curve (Fig. 19 A). In this case, the treatment with 1x10-4 M BPA affects the cells 
viability more than the treatment with 5x10-2 M glucose, while the time-response 
curves of treatments with 1x10-6 M and 1x10-9 M BPA are closer. However, comparing 
the results of ATPLiteTM assay with those of MTT is possible to see that there is not a 
significant reduction in ATP production, except at the highest concentration (Fig. 19 
B, C and D).  
3.8 BPA promotes apoptosis 
The already reported results suggest that the exposure to BPA is able to affect the 
viability of the pancreatic cells. Furthermore, given the relevance as key organelles of 
the mitochondria for -cell function, it is well known that their dysfunction or defects 
can trigger the apoptosis [245]. In this sense, we decided to assess the apoptosis at the 
single cell level with a TUNEL assay, by IF, on dispersed islets. For the realization of 
the TUNEL assay, we treated the samples 1x10-4, 1x10-6, 1x10-9 M BPA. The cells 
were stained with DAPI, to evidence the nuclei, and with the TUNEL reagent (Fig. 20). 
In the untreated samples there is no strong staining from TUNEL, only a weak 
background which indicates the absence of apoptosis (Fig. 20 A). In the panels 
representing the exposition to 1x10-4, 1x10-6 M BPA (Fig. 20 B and C) a considerable 
signal of apoptosis is visible, with 25% of the cells displaying a strong apoptotic signal. 
In the cells exposed to 1x10-9 M BPA (Fig 20 D), we could observe that apoptosis was 
also present to a less extent then the higher concentrations.  
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Fig. 20 Pancreatic islet cells apoptosis induced by treatment with diverse concentration of BPA 
for 48 h as determined by IF-TUNEL assay. Representative images of apoptotic cells stained with 
DAPI, to evidence nuclei, TUNEL reagent, to notice apoptosis and merged stains at 40x 
magnification. Islet cells were exposed to: vehicle only (DMSO) (A), 1x10-4M (B), 1x10-6 M (C), 
1x10-9M (D) BPA or DNase 2000U (Positive Control) (E).  
 
A 
B 
C 
D 
E 
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3.9 BPA, but not E2, enhances Bax gene transcription specifically in murine 
pancreatic islets 
After the TUNEL assay and the evidence that 1x10-9 M BPA could induce apoptosis 
in murine pancreatic islet cells, the analysis of the expression of a pro-apoptotic gene 
during was the chosen approach. We opted to determine the expression of Bax gene 
since it has been reported that induces cell death by acting on the mitochondria [300] 
and appears to be an essential gateway to mitochondrial dysfunction required for cell 
death in response to diverse stimuli [301]. We assessed the Bax transcript level in RNA 
prepared from islets or hepatocytes treated with 1x10-9 M BPA for 24 hours, 48 hours 
and 7 days. At this concentration in islets, a significant increase in the cellular amount 
of Bax mRNA in all the time-point analyzed was observed (Fig. 21 A). As expected, 
according to MTT results, the highest effect was observed at 48 hours with an up-
regulation of 2.5 time compared to control, while at 24h and 7 days the effect was lower 
but still significant (1.30 and 1.38, respectively). Moreover, the incubation of islets 
with the same concentration of E2 did not replicate this effect. Conversely, E2 
protected the islets from apoptosis (-1.37, Fig. 21 B). In addition, to confirm he 
specificity of the effects 1x10-9 M BPA in our model, we performed the same assay on 
murine hepatocytes treated for 24h and 48h. As is visible in figure 21 C, the BPA 
induced a very mild increase of the gene expression, while at 48h this effect was no 
longer visible (Fig. 21 C). 
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3.10 BPA, in murine pancreatic islets, induces apoptosis enhancing ROS level 
and triggering NF-kB pathway 
Recently we published that, in rat thyroid follicular cells, FRTL-5, low concentrations 
of BPA (ranging from 1x10-9 to 1x10-4 M) enhanced the expression of the thyroglobulin 
(Tg) gene acting on its promoter. Interestingly, two different antiestrogens, ICI 182780 
(ICI) and tamoxifen (TAM) were not able to affect the BPA activity on the Tg-
promoter, even if the estrogen receptor signaling was inducible by estrogen in this 
cellular setting. Upon the analysis of Tg promoter organization, we developed two 
FRTL-5 reporter cell lines stably expressing the luciferase gene under the control of a 
 
Fig. 21 Expression alterations of Bax gene in murine pancreatic islets and hepatocytes as 
determined by qRT-PCR. A: islets were cultured in presence or absence of 1x10-9M BPA for 24 h 
or 48 h or 7 days. B: islets were cultured in presence or absence of 1x10-9M E2 for 48 h s. C: 
primary hepatocytes were cultured in presence or absence of 1x10-9M BPA for 24 h or 48 h. Data 
are reported as fold change values calculated as ratio between average gene expression in 
control and treated islets or cells. The qRT-PCR results are expressed as the mean ± standard 
deviation of at least three independent experiments.  
* p-value<0.05; **p-value<0.01; ***p-value<0.001 compared with untreated control cells 
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NF-kB and RAR/RXR dependent promoters.  We shown that BPA is able to induce the 
NF-kB and RAR/RXR signalling in our experimental condition [139]. Therefore, these 
results suggest that that BPA could exert its activity on this cell line not exclusively 
through ER signaling but involving also other cellular pathways. The activity of other 
nuclear receptors can be deregulated by BPA by different mechanisms (reviewed in 
[302]). Thus, we asked whether the BPA treatment could alter the pancreatic gene 
expression and induce apoptosis acting on the same or other transcription pathways. 
To this aim, we have identified by bioinformatic analysis (Genomatix database) the 
transcriptional factors whose binding sites can be predicted in the promoter region (-
1000/+50)bp of our genes of interest (Atp1b1, Atp6v1f, Sod2, Gpx3, Uqcrb, Ndufs4 
and Bax). Among the others, binding sites for NF-kB, retinoic acid receptors 
(RAR/RXR) and Fork head domain factors (FKHD) have been found (table 4). These 
binding sites were present in the promoter of all genes analyzed (Fig. 22). Specifically 
NF-kB had 8 match, RAR/RXR 29 and FKHD 41. 
 
 
 
Considering our previous experience, the bioinformatic analysis, the already shown 
ability of BPA to induce apoptosis and ROS increase [218][145] and their ability to 
activate NFB related transcriptional pathway [303], we decide to focus our attention 
on three diverse pathways and on ROS production. We treated pancreatic murine islets 
for 48h with 1x10-9M BPA and/or with 3mM N-Acetyl-l-cysteine (NAC), 10M BMS 
345541 (BMS), 10 M LY294002 (LY) and 1M ICI. NAC is a ROS scavenger that 
showed the ability to prevent insulin secretion inducted by ROS in rat pancreatic islets 
[304].  
Matrix 
Family 
p-value 
Total 
matches 
Sod2 Ndufs4 Uqcrb Gpx3 Atp1b1 Atp6v1f Bax 
NFkB 0,02 12 4 1 1 1 3 1 1 
RAR/RXR 0,03 33 4 1 4 7 6 6 5 
FKHD 0,03 47 6 6 12 8 2 7 6 
TABLE 4 Binding sites promoter analysis 
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BMS is an IB kinase (IKK) inhibitor able to block the activation of NFB pathway; 
Chen et al., 2011, showed that it is able to improve islets xenograft survival inhibiting 
NFB pathway [305]. LY is a selective inhibitor of PI3K/Akt pathway and downstream 
FKHD activation. Its ability to amplify insulin release in rat pancreatic islets has been 
reported [306]. The already mentioned ICI was used by Alonso-Magdalena et al., 2008, 
to block insulin release inducted by low concentrations of BPA [263].  
At the end of treatment, the RNA was purified and Bax transcript quantified by qRT-
PCR. As reported in Fig. 23, the co-incubation with BPA and ICI or LY did not affect 
the upregulation of Bax, meaning that the apoptotic effect is not induced by the 
activation of ERs or through Akt pathway. Conversely, the presence of NAC and BMS 
significantly decreased the induction of Bax transcript (Fig. 23). Specifically, islets 
treated with BMS alone or BMS and BPA presented Bax mRNA level -1.25 and -1.5 
 
Fig. 22 Promoters bioninformatic analysis. Schematic representation of the transcription 
binding sites predicted by Genomatix software in selected gene promoter fragments 
−1000/+50 bp.  
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times lesser than untreated islets, respectively. While islets treated with NAC alone or 
NAC and BPA had -1.1 and 1.25 fold changes compared to control islets, respectively. 
The data suggest that BPA could affect the islets viability by increasing the intracellular 
ROS levels and activating NfkB pathways 
  
 
Fig. 23 Expression alterations of Bax gene in murine pancreatic islets 
subsequently exposure to BPA and Inhibitors as determined by qRT-PCR.  
Islets were cultured in presence or absence of 1x10-9M BPA, 3x10-3M NAC,  
1x10-5M BMS, 1x10-5M LY or 1x10-6M ICI for 48 h. Data are reported as fold 
change values calculated as ratio between average gene expression in control 
and treated islets. The results are expressed as the mean ± standard deviation 
of at least three independent experiments.  
* p-value<0.05; **p-value<0.01; ***p-value<0.001 compared with BPA only 
treated islets 
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4 Discussion 
BPA is a polycarbonate used in numerous consumer products, including food and water 
containers, lining of food and beverage metal cans and medical tubing, becoming an 
important contaminant due to its ubiquitous presence and the increased exposure 
[106][108].  
BPA exposure is associated with multiple diseases, such as reproductive system, 
nervous system and sexual dysfunctions as well as increased risk of cancer and heart 
disease [179][180]. Epidemiological correlation between BPA and the occurrence of 
diabetes has been found [307]. In vitro and in vivo studies have shown that exposure 
to low doses of BPA elicits alteration in insulinemia, pancreatic islets function and 
glucose homeostasis [238]. Moreover, in WAT, BPA is able to suppress the 
adiponectin and increase inflammatory cytokines (Tnf-, IL-6,) release [108]. Given 
these effects, its prevalence in the environment and the presence in serum from humans 
worldwide, BPA may play a role in the rapid increase of incidence of metabolic 
disorders. 
In this work, we studied the effects of BPA on ex vivo primary murine pancreatic islets 
through a toxicogenomical approach. We reported that exposure could decrease islet 
cells viability, alter the transcriptome, interfere with mitochondrial activity and other 
specific cell functions and increase the apoptosis in a dose-dependent manner. More 
importantly we found that BPA apoptosis pathway triggering is dependent to 
intracellular ROS levels elevation and activation of NFkB pathway. 
We chose to study the effects of three different concentrations of BPA, 1x10-4 M, 
known to be cytotoxic, 1x10-6M and 1x10-9M to mimic worker and worldwide 
population exposure, respectively [182][183]. We focused on the effects of 1x10-9 M 
BPA, as it can be considered the environmental concentration. Moreover, the lower 
concentration used in this study can be considered a ‘low dose’ because estimates of 
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circulating levels of BPA at the LOAEL define an equivalent low-dose concentration 
as 2.19x10-7M in vitro culture studies [125][126]. 
To begin we inspected the effects of BPA on morphology of the pancreatic islets, after 
48 hours of treatment. We could not observe relevant diameter or other gross 
alterations. On the other hand, from the three chosen concentrations we were able to 
observe that both 1x10-4 M, and 1x10-6 M BPA treatments appear to induce some 
changes in the morphology with the whole islet gaining a granulated aspect and a 
precocious loss of the necrotic central core (Fig 12). The formation of a necrotic core 
is typical of ex vivo cultured islets and is due to hypoxia of the cells in the central area. 
The islet throw out this core after few days in culture. Probably, the treatment with 
BPA loosens the compactness of the cells and allows a faster ejection of the necrotic 
core.  
To investigate the cytotoxic effect of BPA we performed an MTT assay. We found that 
BPA significantly reduced islet cells viability in a dose- and time-dependent manner. 
Noteworthy, that 1x10-9M BPA decrease the viability of 20% after 48 hours of 
treatment (Fig. 13), even if longer incubations did not induced further decrease, this 
suggest that low concentration of BPA could have an impact on islets viability and be 
detrimental for their health status. 
The transcriptome analysis has been successfully applied in testing low doses EDCs in 
biological systems to identify non-standard toxicological endpoints [310]. This is 
particular powerful in the analysis of compounds, such as BPA, capable exerting 
effects at low doses and with a non-monotonic dose-response curve. The 
toxicogenomical approach through RNA microarray analysis allowed us to have a 
snapshot of the global status of the islets, indicating the main functions impaired and 
the further direction to follow to identify the processes and the pathways affected by 
BPA exposure. 
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The analysis of microarray data gave a short list of 29 downregulated DEGs (table 3). 
Among genes involved in generic cell functions, there was a large part of genes 
encoding for mitochondrial localized proteins, indicating the mitochondrion as the key 
organelle affected by BPA exposure. This was confirmed by IPA analysis that 
identified mitochondrial dysfunction and oxidative phosphorylation as the most 
deregulated canonical pathways (Fig 16). Mitochondria are critical for the regulation 
of -cell mass and maintenance of -cell function through the coupling of glucose 
stimulus to insulin release [170][185]. Indeed, a recent study indicated that Wistar rat 
offspring perinatally exposed to 50 g/kg/day BPA present profound mitochondrial 
structural defects in -cells that precede any observable alterations in glucose 
homeostasis [311]. Moreover, exposure of isolated rat islets to 1.1x10-7 M BPA has 
also been reported to cause mitochondrial swelling, to alter the expression of typical 
mitochondrial genes, to decrease the activity of the mitochondrial respiratory enzyme 
COX IV, and to reduce ATP content [281]. Nevertheless, mitochondrial dysfunction 
at so low concentration of BPA in analysis of endocrine pancreatic islets was not yet 
found. Further experiments will be performed to analyze the proper mitochondrial 
functionality. Specifically we are current testing the BPA effects on mitochondrial 
morphology and abundance, on mitochondrial membrane potential and on 
mitochondrial ROS production. 
From the list of genes obtained, we decided to further analyze 9 genes according to the 
function of the protein for which encode. For better understand the onset and the 
duration of these mitochondrial effects, we investigated, by qRT- PCR analysis, two 
more time-points, 24 hours and 7 days, beside the 48 hours for the microarray 
validation. The results showed 1x10-9M BPA produced greater effects in a range from 
24 to 48 hours, while longer exposition did not produce further changes in gene 
expression (Fig. 17). Actually, after 7 days of treatment, the transcript level of most of 
the genes goes back up. This contradictory data could be explained with the shelf life 
in vitro of explanted primary islets. After 7 days of culture, they may lost many of their 
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characteristics, their metabolic and communication functionality. Most of the genes 
had the highest inhibition at 48 hours, confirming the correct choice of this time point 
for the microarray experiments, while only 2 genes out of 9 had a greater inhibition at 
24 hours.  
Among the genes we decided to further analyze, Ndufs4 and Uqcrb, both encoding for 
sub-unit of the mitochondrial respiratory chain. The down-regulation of these two 
genes (Fig. 17 B), as well as of ATP6v1f (Fig. 17 C), pointed to an impaired oxidative 
phosphorylation that may cause defects in glucose stimulated ATP production. In -
cells, the levels of ATP directly regulate the ATP dependent K+ channels that in turn 
regulates the ability of the cell to secrete insulin. Adding that Atp1b1, also down-
regulated in our experiments (Fig. 17 C), is a subunit of K+ channels, we can 
hypothesize that BPA-induced mitochondrial damage might play a critical role in the 
development of pancreatic islets dysfunction. To support this hypothesis other authors 
epidemiologically linked type II diabetes and deregulation of the expression of gene 
involved in oxidative phosphorylation [312]. Actually, we tried to verify if there was a 
reduction of intracellular levels of ATP but we obtained significant results only at 
highest concentration (Fig. 19). Probably a low concentration of BPA, such 1x10-9M, 
is not able to produce this functional defect but predispose the cells to develop this type 
of damage. We are currently testing this hypothesis by examining the response of the 
islet cells to a co-incubation with 1x10-9M BPA and 3x10-2M glucose. We hypothesize 
that BPA exposure (or pre-exposure) could affect the ability of islet cells to have an 
appropriate response to an overcharge of their function. 
Furthermore, down-regulation of expression of gene encoding proteins involved in the 
respiratory chain could lead to leakage of electrons and to higher production of ROS 
and other free radicals. Interestingly, we also found deregulated the expression of two 
genes, Sod2 and Gpx3 (Fig.17 A), which encode proteins exactly assigned to ROS and 
free radicals scavenging. Therefore, the BPA could damage the islets with a dual effect, 
enhancing the oxidative stress and lowering the cell defensive system and, thus, 
71 
 
promoting the apoptosis. Indeed the experiments shown in fig 20 showed that NAC (a 
well-known antioxidant) is able to decrease the expression of the pro-apoptotic Bax 
gene. 
Iars encode isoleucine-tRNA synthetase. Isoleucine is an amino acid of predominant 
importance in human mitochondria [313]. For these reasons a loss of isoleucylation 
efficiency are expected to lead to important impairment of protein synthesis [296]. The 
downregulation of this gene expression, inducted by BPA (Fig. 17 D), could enhance 
the misfolding of mitochondrial localized proteins and promote their aggregation.  
Finally, BPA showed to decrease the expression of Vapa (Fig. 17 D), which protein is 
involved I tight junction formation. Its downregulation could be linked to the observed 
reduced compactness of islets (Fig. 12), a clear sign of non-healthy islets. 
As we expected, a low concentration of BPA, such as 1x10-9M, does not produce large 
alterations but may affect several cellular system and make the islets not able to 
efficaciously response to more insults. This bad predisposition is important in 
multifactorial and complex pathologies such as metabolic disorders. 
One potential consequence of mitochondrial damage is the increase in apoptosis. 
Mitochondrial dysfunction ultimately leads to apoptosis and contributes to the 
development of diabetes [245]. In this sense, here we demonstrated that BPA exhibit a 
dose dependent role in the apoptosis of the islet cells, as it is visible in the figure 20, 
probably via activation of the mitochondrial pathway, as the up-regulation of Bax gene 
expression suggest (Fig. 21). 
Federici et al. demonstrated in in vitro human islets cultured that high glucose induced 
apoptosis is consecutive to an increasing of Bax mRNA levels [314]. In our 
experiments, the expression of Bax was increased in all the time points tested when 
compared to control. In agreement with the MTT and the TUNEL assay, at 48 hours 
Bax reached 2.5-fold expression evidencing the pathway through which the apoptosis 
occurred.  
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The data of this study clearly point to a specific mechanism of action of BPA in 
pancreatic islet cells (Figs 18 e 21). Previous studies clearly demonstrated that BPA is 
a xenoextrogen acting through nuclear ERs and membrane bound ERs [238], but the 
data in figure 23 suggest that, in pancreatic islets ERs are not involved in the triggering 
of apoptosis. Indeed we propose that BPA, besides its estrogenic actions, promotes cell 
death increasing intracellular ROS and activating NFkB pathway. These results are in 
agreement with the findings that BPA exposure increase ROS cellular amount 
regulating NFkB pathway [315]. Figure 23, we showed that BMS, inhibitor of NFkB 
pathway, and NAC (antioxidant compound) are able to block the Bax transcript cellular 
level upon exposure to BPA (in co-treatment conditions). They exert to less extent the 
same effects also in BPA untreated islets, suggesting that the NFkB pathway is 
activated in the stressing condition deriving from the purification and culture of the 
islets.  
Further functional experiments will be necessary to completely elucidate the 
mechanisms through which BPA promotes apoptosis in murine pancreatic islets. The 
results of this work are an in vitro (even if ex vivo) conceptual prove of the detrimental 
effects of BPA on pancreatic islets. Nevertheless, data from in vivo studies and longer 
exposure to low doses of BPA are required. To this aim, we are programming to 
transplant BPA treated islets in obese and diabetic mouse models that will be further 
treated with BPA intraperitoneally injected or oral administered to mimic the effects 
of environmental concentrations of BPA in metabolic disorders susceptible population. 
Furthermore, all the results will be confirmed in vivo in a zebrafish transgenic cell line 
carrying the GFP coding sequence under the control of the insulin promoter. Thus, the 
islets can be recognized and picked up from animal treated with environmental doses 
of BPA starting from fertilization and exposed for long time. 
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5 Conclusions 
This work is a contribution to clarify the role of the endocrine disruption by BPA in 
the function of pancreatic islets. Data from the current study overwhelmingly indicate 
that BPA affects the viability and function of normal murine pancreatic islets and 
accelerates their rate of apoptosis in a dose-dependent manner. This is adding new 
knowledge on the role of BPA on diabetes development and progression that, until 
now, has been focused on the insulin resistance. We suggest that exposure to BPA 
alters the expression of key genes, induces mitochondrial defects, raises the 
intracellular ROS levels and ultimately triggers the apoptosis of islet cells. Despite the 
published role of  estrogen and BPA on the secretion of insulin, here we show that the 
regulation of transcript level by BPA is not carried out through the estrogen receptors 
but involve the NFkB pathway, probably among others. The demonstration that BPA 
at environmental dose is able to affects the islets functions and viability are in 
agreement with the link between metabolic dysfunctions and BPA exposure proposed 
in literature and confirm that BPA could be an important environmental factor in 
metabolic disorders onset.  
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